

*Expenditure  
and  
Prescriptions  
Twelve Months  
to  
30 June  
2016*

PBS Information  
Management Section  
Pharmaceutical Policy Branch



Pharmaceutical Benefits Scheme

This publication and previous editions can be accessed via the internet:  
<http://www.pbs.gov.au/info/browse/statistics>

Please direct enquiries about this publication or requests for complimentary copies via:

Surface mail: Director  
PBS Information Management Section  
Pharmaceutical Policy Branch, MDP 900  
Department of Health  
GPO Box 9848 Canberra ACT 2601

E-mail: [pbsstats@health.gov.au](mailto:pbsstats@health.gov.au)

Report production: Gareth Thomas, Peter Marlton.

Thanks to the following people for their help in the access and provision of data and information used in this report: Sonja Davis, Matthew Fairhall, Robert Nichols, Nikolai Tsyganov, Dan Troselj, Erin Thorncraft, Karen Prstec, Christopher Parker, Simon Wells, Andrew Kopras.

### Important Information

Unless otherwise indicated this publication has been produced using data provided to the Department of Health by the Department of Human Services. The figures reported in this publication relate to the value (benefit) or volume of PBS prescriptions that have been processed by the Department of Human Services. They refer only to paid services processed from claims presented by approved suppliers. They do not include any adjustments made against claims, any manually paid claims or any benefits paid as a result of retrospective entitlement or refund of patient contributions.

PBS Expenditure includes the following patient categories:

- General - Non-Safety Net (Ordinary)
- General - Safety Net
- Concessional - Non-Safety Net (Ordinary)
- Concessional - Safety Net
- Doctor's Bag

The patient category refers to the patient's eligibility status at the time of supply of the benefit. General patients hold a Medicare card, Concessional patients hold a Medicare card and one of the following cards from Centrelink:

- Pension Concession Card
- Commonwealth Seniors Health Card
- Health Care Card

There are two safety net thresholds – one for General patients and the other for Concessional patients.

From 1 January 2016, the general patient safety net threshold was **\$1,475.70**. When patients and/or their families reached this amount, they could apply for a Safety Net Concession Card and pay only **\$6.20** per prescription for the rest of the calendar year. The concessional safety net threshold was **\$372.00**. Once patients and/or their families reached this amount, they could apply for a Safety Net Entitlement Card and receive items free of charge for the rest of the calendar year.

The Patient Contribution, Total Cost and Average Price amounts do not include brand or therapeutic premiums.

Caution should be exercised in referring to the breakdown by patient category in Table 20(a) on page 27 and Table 20(b) on page 30, because of a past problem in data supplied by the Department of Human Services whereby a number of General Safety Net scripts were wrongly allocated to Concessional Non-Safety Net. This problem has been fixed for 2008-09, but the 2006-07 and 2007-08 allocations of scripts and expenditure by patient category were inaccurate and not strictly comparable to the corresponding 2008-09 and later years' numbers.

The Department of Health has taken every care to ensure the data supplied is accurate but does not warrant that the data is error free and does not accept any liability for errors or omissions in the data.

<b>Contents</b>	<b>Summary</b>	
Table 1(a)	PBS Expenditure on Accrual Accounting Basis	1
Table 1(b)	PBS Section 100 Programmes on Accrual Accounting Basis	1
Table 2(a)	PBS Section 85 Prescription Volume	2
Table 2(b)	PBS Section 85 Government Cost	2
Table 2(c)	RPBS Section 85 Prescription Volume and Government Cost	2
Table 3(a)	PBS Prescription Volume, Government Cost, Patient Contributions and Average Price	3
Table 3(b)	PBS Prescription Volume and Government Cost by Monthly Summary	3
Table 4(a)	PBS Prescription Volume for 4 Financial Years	4
Table 4(b)	PBS Expenditure for 4 Financial Years	4
Table 5	PBS Processing by State	5
Table 6	PBS Prescription Volume, Government Cost and Average Government Cost/Script for 4 Financial Years	6
Table 7	ATC Main Group Comparison	7
Table 8(a)	Significant Drug Groups (ATC Level 2) by Highest Government Cost	8
Table 8(b)	Significant Drug Groups (ATC Level 2) by Highest Script Volume	9
Table 9(a)	Significant Drugs Sorted by Highest Change to Government Cost	10
Table 9(b)	Significant Drugs Sorted by Highest Change to Script Volume	11
Table 10(a)	PBS Drugs (Generic Name) Sorted by Highest Government Cost	12
Table 10(b)	PBS Drugs (Generic Name) Sorted by Highest Script Volume	13
Table 11(a)	PBS Item Codes Sorted by Highest Government Cost	14
Table 11(b)	PBS Item Codes Sorted by Highest Script Volume	15
Table 12	ATC Level 2 Drug Groups Sorted by Highest Script Volume	16
Table 13	PBS Drugs (Generic Name) Sorted by Highest Script Volume	17
Table 14	PBS Item Codes Sorted by Highest Script Volume	18
Table 15	PBS Processing by Formulary	19
Table 16(a)	Top 20 Responsible Persons by Total Cost	20
Table 16(b)	Top 20 Responsible Persons by Market Share (Scripts)	21
<b>Supplement 1</b>		
Table 17(a)	Safety Net Card Issues - Persons Covered	22
Table 17(b)	Safety Net Card Issues, Number of Cards	23
Table 18	Pharmacies and Friendly Societies	24
Table 19	Special Patient Contributions	25
Table 20(a)	Pharmaceutical Benefits Scheme, Prescriptions - History	26-27
Table 20(b)	Pharmaceutical Benefits Scheme, Government Cost - History	28-30
<b>Supplement 2</b>	PBS Information Line Report	31-33
<b>Supplement 3</b>	National Diabetes Services Scheme (NDSS)	34-35
Chart	National Diabetes Scheme Government Cost	36
<b>Supplement 4</b>	Community Pharmacy Agreement (CPA) Expenses Report 2015-16	37
Table 21	Actual Cost of Each Major Component	38
Table 22	Remuneration for Community Pharmacies and Friendly Societies	39
Table 23	Professional Pharmacy Programmes	40
Table 24	Community Services Obligation (CSO)	41
Table 25	\$1 Discount for Community Pharmacies	42

## Summary of Pharmaceutical Benefits Scheme

2015-2016

Total Pharmaceutical Benefits Scheme (PBS) government expenditure (both Section 85 and Section 100) on an accrual accounting basis for the 2015-2016 financial year was **\$10,838.0 million**, compared with \$9,072.1 million for the previous year. This is an increase of **19.5%**.

The majority of the Expenditure and Prescriptions Report and the remainder of this summary refer to PBS Section 85 data reported on a cash accounting basis by date of processing.

Total PBS prescription volumes decreased by 1.9% to a total of 208.0 million for 2015-16, compared to 212.1 million for the previous year.

Government expenditure amounted to **\$7,964.9 million** which was **85.1%** of the total cost of PBS prescriptions. The remainder was patient contributions that amounted to **\$1,394.2 million**, down from \$1,465.9 million in the previous twelve-month period.

The majority of government expenditure on PBS prescriptions was directed towards concessional cardholders (**\$6,044.8 million, 75.9% of the total**). This is compared to concessional expenditure of \$5,503.9 million in the previous period (77.4% of the total).

The average dispensed price per prescription of PBS medicines **increased** to **\$45.00** for 2015-16 (\$40.45 for the previous financial year). The average government cost of these scripts was **\$38.29** for the same period (\$33.54 for 2014-15).

The three drugs with the highest cost to government were **Ledipasvir + Sofosbuvir (\$357.9 million)**, **Adalimumab (\$334.7 million)** and **Ranibizumab (\$217.8 million)**. The PBS drugs most frequently dispensed were **Atorvastatin**, followed by **Esomeprazole** and then **Rosuvastatin**. See Table 10(b) for details.

*Note that there may be minor differences in data reported in this publication compared to previous editions of Expenditure and Prescriptions. This is because of a different treatment of Closing the Gap prescriptions, and the receipt of some late adjustments to claims from pharmacies due to the new streamlined claiming process.*

**Table 1(a): PBS Expenditure on Accrual Accounting Basis, 2014-15 & 2015-16.**

Category	2014-15	Percentage of Total	2015-16	Percentage of Total	Change	Change Percentage
Section 85 - Concessional	\$5,383,326,663	59.3%	\$6,172,196,919	56.9%	788,870,256	14.7%
Section 85 - General	\$1,505,698,622	16.6%	\$1,912,963,069	17.7%	407,264,448	27.0%
Doctors' Bag	\$17,261,555	0.2%	\$17,218,481	0.2%	-43,075	-0.2%
Section 100*	\$2,155,417,984	23.8%	\$2,724,933,327	25.1%	569,515,343	26.4%
Safety Net Cards	\$10,421,579	0.1%	\$10,673,298	0.1%	251,720	2.4%
<b>Total</b>	<b>\$9,072,126,403</b>	<b>100.0%</b>	<b>\$10,837,985,095</b>	<b>100.0%</b>	<b>1,765,858,692</b>	<b>19.5%</b>
<b>Total Including Revenue</b>	<b>\$8,498,906,852</b>		<b>\$10,143,081,604</b>		<b>1,644,174,753</b>	<b>19.3%</b>

\* Individual S100 programmes are shown in Table 1(b).

**Table 1(b): PBS Section 100 Programmes on Accrual Accounting Basis, 2014-15 & 2015-16.**

Category	2014-15	Percentage of Total	2015-16	Percentage of Total	Change	Change Percentage
Highly Specialised Drugs	\$1,209,370,339	56.1%	\$1,583,754,673	58.1%	\$374,384,335	31.0%
Chemotherapy (EFC & CPAP)	\$608,601,391	28.2%	\$702,421,712	25.8%	\$93,820,321	15.4%
In Vitro Fertilisation	\$91,782,156	4.3%	\$143,529,836	5.3%	\$51,747,680	56.4%
Special Authority Program	\$101,261,002	4.7%	\$139,208,937	5.1%	\$37,947,935	37.5%
Opiate Dependence Treatment Program	\$43,771,943	2.0%	\$49,404,634	1.8%	\$5,632,691	12.9%
Aboriginal Health Services (GST exclusive)	\$40,598,087	1.9%	\$40,323,041	1.5%	-\$275,047	-0.7%
Botulinum Toxin Program (incl. Dysport)	\$28,135,783	1.3%	\$36,473,730	1.3%	\$8,337,947	29.6%
Human Growth Hormones	\$31,270,445	1.5%	\$29,098,993	1.1%	-\$2,171,452	-6.9%
Paraplegic and Quadriplegic Program	\$451,730	0.0%	\$494,319	0.0%	\$42,588	9.4%
Continuing Medication Program	\$175,108	0.0%	\$223,453	0.0%	\$48,345	27.6%
<b>Total</b>	<b>\$2,155,417,984</b>	<b>100.0%</b>	<b>\$2,724,933,327</b>	<b>100.0%</b>	<b>\$569,515,343</b>	<b>26.4%</b>

**Notes:**

Expenditure figures refer to payments made through Department of Human Services and directly from the Department of Health. This data reflects the current definitions of Section 100 programs as published on [www.pbs.gov.au](http://www.pbs.gov.au).

Table 2(a): PBS Section 85 Prescription Volume (on Cash Accounting Basis), 2014-15 and 2015-16.

	Script Volume 2014-15	Percentage 2014-15	Script Volume 2015-16	Percentage 2015-16	Script Volume Change	Script Volume Change Percentage
Concessional Safety Net	44,277,679	20.9%	44,119,861	21.2%	-157,818	-0.4%
Concessional Non-Safety Net	147,979,717	69.8%	146,529,394	70.5%	-1,450,323	-1.0%
<i>Total Concessional</i>	<i>192,257,396</i>	<i>90.7%</i>	<i>190,649,255</i>	<i>91.7%</i>	<i>-1,608,141</i>	<i>-0.8%</i>
General Safety Net	3,544,902	1.7%	3,180,897	1.5%	-364,005	-10.3%
General Non-Safety Net	15,902,515	7.5%	13,770,978	6.6%	-2,131,537	-13.4%
<i>Total General</i>	<i>19,447,417</i>	<i>9.2%</i>	<i>16,951,875</i>	<i>8.2%</i>	<i>-2,495,542</i>	<i>-12.8%</i>
Doctors Bag	380,376	0.2%	388,859	0.2%	8,483	2.2%
<b>Total (Over Co-payment)</b>	<b>212,085,189</b>	<b>100.0%</b>	<b>207,989,989</b>	<b>100.0%</b>	<b>-4,095,200</b>	<b>-1.9%</b>
Under Co-payment	79,031,192		83,043,126		4,011,934	5.1%

Table 2(b): PBS Section 85 Government Cost (on Cash Accounting Basis), 2014-15 and 2015-16.

	Government Cost 2014-15	Percentage 2014-15	Government Cost 2015-16	Percentage 2015-16	Government Cost Change	Government Cost Change Percentage
Concessional Safety Net	\$1,380,416,342	19.4%	\$1,413,858,158	17.8%	\$33,441,816	2.4%
Concessional Non-Safety Net	\$4,123,482,128	58.0%	\$4,630,980,302	58.1%	\$507,498,174	12.3%
<i>Total Concessional</i>	<i>\$5,503,898,470</i>	<i>77.4%</i>	<i>\$6,044,838,460</i>	<i>75.9%</i>	<i>\$540,939,990</i>	<i>9.8%</i>
General Safety Net	\$129,523,975	1.8%	\$118,821,879	1.5%	-\$10,702,096	-8.3%
General Non-Safety Net	\$1,463,256,600	20.6%	\$1,785,357,915	22.4%	\$322,101,315	22.0%
<i>Total General</i>	<i>\$1,592,780,575</i>	<i>22.4%</i>	<i>\$1,904,179,793</i>	<i>23.9%</i>	<i>\$311,399,219</i>	<i>19.6%</i>
Doctors Bag	\$16,340,036	0.2%	\$15,887,150	0.2%	-\$452,886	-2.8%
<b>Total (Over Co-payment)</b>	<b>\$7,113,019,081</b>	<b>100.0%</b>	<b>\$7,964,905,404</b>	<b>100.0%</b>	<b>\$851,886,323</b>	<b>12.0%</b>

Table 2(c): RPBS Section 85 Prescription Volume and Government Cost (on Cash Accounting Basis), 2014-15 and 2015-16.

	Script Volume 2014-15	Script Volume 2015-16	Script Volume Change	Script Volume Change Percentage
<b>Repatriation (Safety Net And Non-Safety Net)</b>	11,650,058	10,546,973	-1,103,085	-9.50%

	Government Cost 2014-15	Government Cost 2015-16	Government Cost Change	Government Cost Change Percentage
<b>Repatriation (Safety Net And Non-Safety Net)</b>	\$328,683,777	\$317,478,782	-\$11,204,995	-3.40%

**Table 3(a): PBS Prescription Volume, Government Cost, Patient Contributions and Average Price.**  
Section 85 only.

Patient Category		Scripts	Government Cost	Patient Payments	Total Cost*	Ave. Price**
2015-16	Concessional Non-Safety Net	146,529,394	\$4,630,980,302	\$880,965,644	\$5,511,945,946	\$37.62
	Concessional Safety Net	44,119,861	\$1,413,858,158	\$0	\$1,413,858,158	\$32.05
	<i>Total Concessional</i>	<i>190,649,255</i>	<i>\$6,044,838,460</i>	<i>\$880,965,644</i>	<i>\$6,925,804,104</i>	<i>\$36.33</i>
	General Non-Safety Net	13,770,978	\$1,785,357,915	\$494,124,051	\$2,279,481,966	\$165.53
	General Safety Net	3,180,897	\$118,821,879	\$19,115,443	\$137,937,321	\$43.36
	<i>Total General</i>	<i>16,951,875</i>	<i>\$1,904,179,793</i>	<i>\$513,239,494</i>	<i>\$2,417,419,287</i>	<i>\$142.60</i>
	<b>Total (without DB)</b>	<b>207,601,130</b>	<b>\$7,949,018,254</b>	<b>\$1,394,205,138</b>	<b>\$9,343,223,391</b>	<b>\$45.01</b>
	Doctors Bag	388,859	\$15,887,150	\$0	\$15,887,150	\$40.86
<b>Total (with DB)</b>	<b>207,989,989</b>	<b>\$7,964,905,404</b>	<b>\$1,394,205,138</b>	<b>\$9,359,110,541</b>	<b>\$45.00</b>	

**Table 3(b): PBS Prescription Volume and Government Cost by Monthly Summary.**  
Section 85 only; excl. Drs Bag.

		Subsidised Volume	Under Co-payment Volume	Government Cost	Patient Payments	Total Cost*	Ave. Price**
2014	Jul	15,039,540	5,886,412	\$506,992,609	\$117,522,491	\$624,515,100	\$41.52
	Aug	17,336,668	6,522,203	\$591,835,926	\$126,555,096	\$718,391,022	\$41.44
	Sep	15,253,990	5,759,048	\$525,922,658	\$104,411,365	\$630,334,023	\$41.32
	Oct	15,142,605	5,591,087	\$523,685,590	\$97,798,971	\$621,484,560	\$41.04
	Nov	17,070,761	5,956,825	\$578,508,821	\$100,120,764	\$678,629,585	\$39.75
	Dec	14,830,826	5,157,300	\$506,938,302	\$81,265,643	\$588,203,944	\$39.66
2015	Jan	17,099,341	5,303,545	\$584,972,550	\$84,518,510	\$669,491,060	\$39.15
	Feb	22,310,592	7,806,337	\$754,846,933	\$139,977,649	\$894,824,581	\$40.11
	Mar	17,084,198	6,727,219	\$570,074,282	\$135,603,689	\$705,677,971	\$41.31
	Apr	13,424,879	5,116,124	\$441,403,173	\$108,789,093	\$550,192,265	\$40.98
	May	27,432,957	10,845,471	\$882,973,031	\$218,528,092	\$1,101,501,122	\$40.15
	Jun	19,678,456	8,359,621	\$628,525,171	\$150,812,912	\$779,338,083	\$39.60
	<b>Total</b>	<b>211,704,813</b>	<b>79,031,192</b>	<b>\$7,096,679,044</b>	<b>\$1,465,904,274</b>	<b>\$8,562,583,318</b>	<b>\$40.45</b>
2015	Jul	20,250,296	8,389,612	\$673,138,802	\$146,520,204	\$819,659,007	\$40.48
	Aug	17,509,745	7,228,713	\$597,964,572	\$116,781,942	\$714,746,514	\$40.82
	Sep	17,547,155	6,975,896	\$620,741,836	\$108,753,024	\$729,494,860	\$41.57
	Oct	17,329,872	6,596,402	\$614,704,601	\$98,710,836	\$713,415,436	\$41.17
	Nov	17,459,012	6,015,085	\$619,833,165	\$90,276,723	\$710,109,888	\$40.67
	Dec	21,073,937	6,643,392	\$751,956,879	\$96,742,354	\$848,699,233	\$40.27
2016	Jan	14,757,577	5,827,856	\$532,571,972	\$95,519,582	\$628,091,554	\$42.56
	Feb	14,919,636	6,280,841	\$546,676,725	\$118,340,414	\$665,017,139	\$44.57
	Mar	18,364,450	7,659,934	\$708,581,712	\$143,720,837	\$852,302,549	\$46.41
	Apr	15,642,484	7,183,034	\$674,911,731	\$127,645,260	\$802,556,991	\$51.31
	May	15,834,065	6,873,824	\$757,422,906	\$123,944,643	\$881,367,549	\$55.66
	Jun	16,912,901	7,368,537	\$850,513,353	\$127,249,319	\$977,762,671	\$57.81
	<b>Total</b>	<b>207,601,130</b>	<b>83,043,126</b>	<b>\$7,949,018,254</b>	<b>\$1,394,205,138</b>	<b>\$9,343,223,391</b>	<b>\$45.01</b>

\* Total Cost includes cost to the patient and cost to the government.


\*\* Average Price is Total Cost divided by Script Volume.

**Table 4(a): PBS Prescription Volume for 4 Financial Years.**

Section 85 only; excl. Drs Bag.

Script Volume	2012-13	2013-14	2014-15	2015-16
Over Co-payment	197,328,974	209,964,792	211,704,813	207,601,130
Under Co-payment	62,019,467	72,322,449	79,031,192	83,043,126
<b>Total</b>	<b>259,348,441</b>	<b>282,287,241</b>	<b>290,736,005</b>	<b>290,644,256</b>

**Graph for Table 4(a): PBS Prescription Volume for 4 Financial Years.**




**Table 4(b): PBS Expenditure for 4 Financial Years.**

Section 85 only; excl. Drs Bag.

Expenditure	2012-13	2013-14	2014-15	2015-16
Government Cost	\$7,088,662,996	\$7,317,674,872	\$7,096,679,044	\$7,949,018,254
Patient Cost	\$1,482,680,489	\$1,528,717,760	\$1,465,904,274	\$1,394,205,138
<b>Total</b>	<b>\$8,571,343,484</b>	<b>\$8,846,392,633</b>	<b>\$8,562,583,318</b>	<b>\$9,343,223,391</b>

**Graph for Table 4(b): PBS Expenditure for 4 Financial Years.**



**Table 5: PBS Processing by State, 2015-16.**

Section 85 only; excl. Drs Bag.

<b>Script Volume</b>	<b>NSW</b>	<b>Vic</b>	<b>Qld</b>	<b>SA</b>	<b>WA</b>	<b>Tas</b>	<b>NT</b>	<b>ACT</b>	<b>Australia</b>
Concessional Non-Safety Net	48,926,689	37,032,188	29,419,750	12,492,608	12,480,504	4,155,651	517,243	1,504,761	146,529,394
Concessional Safety Net	15,424,187	11,033,383	8,732,755	3,788,298	3,421,376	1,267,211	74,877	377,774	44,119,861
General Non-Safety Net	4,505,596	3,178,956	2,825,130	951,285	1,596,021	294,751	125,710	293,529	13,770,978
General Safety Net	1,108,956	756,977	600,774	231,206	340,406	60,992	11,250	70,336	3,180,897
<b>Total</b>	<b>69,965,428</b>	<b>52,001,504</b>	<b>41,578,409</b>	<b>17,463,397</b>	<b>17,838,307</b>	<b>5,778,605</b>	<b>729,080</b>	<b>2,246,400</b>	<b>207,601,130</b>
<b>Government Cost</b>									
Concessional Non-Safety Net	\$1,573,449,809	\$1,174,582,150	\$941,555,561	\$365,847,104	\$377,811,956	\$132,362,330	\$14,995,277	\$50,376,115	\$4,630,980,302
Concessional Safety Net	\$497,338,269	\$347,662,524	\$280,182,051	\$120,271,926	\$111,007,948	\$41,967,864	\$2,250,297	\$13,177,279	\$1,413,858,158
General Non-Safety Net	\$566,900,629	\$471,456,962	\$341,742,080	\$114,983,706	\$201,356,868	\$40,424,181	\$11,902,652	\$36,590,835	\$1,785,357,915
General Safety Net	\$41,575,571	\$28,189,661	\$21,633,815	\$8,566,437	\$13,418,428	\$2,388,467	\$379,257	\$2,670,242	\$118,821,879
<b>Total</b>	<b>\$2,679,264,279</b>	<b>\$2,021,891,297</b>	<b>\$1,585,113,508</b>	<b>\$609,669,173</b>	<b>\$703,595,200</b>	<b>\$217,142,843</b>	<b>\$29,527,482</b>	<b>\$102,814,471</b>	<b>\$7,949,018,254</b>
<b>Total Cost</b>									
Concessional Non-Safety Net	\$1,866,329,320	\$1,400,948,354	\$1,116,812,814	\$441,113,715	\$452,167,628	\$157,369,668	\$17,706,245	\$59,498,202	\$5,511,945,946
Concessional Safety Net	\$497,338,269	\$347,662,524	\$280,182,051	\$120,271,926	\$111,007,948	\$41,967,864	\$2,250,297	\$13,177,279	\$1,413,858,158
General Non-Safety Net	\$726,565,402	\$590,369,358	\$440,695,247	\$149,459,563	\$258,624,228	\$50,865,937	\$15,511,455	\$47,390,776	\$2,279,481,966
General Safety Net	\$48,213,916	\$32,792,064	\$25,229,534	\$9,958,569	\$15,453,145	\$2,751,517	\$442,671	\$3,095,905	\$137,937,321
<b>Total</b>	<b>\$3,138,446,907</b>	<b>\$2,371,772,300</b>	<b>\$1,862,919,646</b>	<b>\$720,803,773</b>	<b>\$837,252,949</b>	<b>\$252,954,986</b>	<b>\$35,910,668</b>	<b>\$123,162,161</b>	<b>\$9,343,223,391</b>
<b>Average Price</b>									
Concessional Non-Safety Net	\$38.15	\$37.83	\$37.96	\$35.31	\$36.23	\$37.87	\$34.23	\$39.54	\$37.62
Concessional Safety Net	\$32.24	\$31.51	\$32.08	\$31.75	\$32.45	\$33.12	\$30.05	\$34.88	\$32.05
General Non-Safety Net	\$161.26	\$185.71	\$155.99	\$157.11	\$162.04	\$172.57	\$123.39	\$161.45	\$165.53
General Safety Net	\$43.48	\$43.32	\$42.00	\$43.07	\$45.40	\$45.11	\$39.35	\$44.02	\$43.36
<b>Total</b>	<b>\$44.86</b>	<b>\$45.61</b>	<b>\$44.80</b>	<b>\$41.28</b>	<b>\$46.94</b>	<b>\$43.77</b>	<b>\$49.25</b>	<b>\$54.83</b>	<b>\$45.01</b>
<b>Population*</b>	7,670,742	5,996,385	4,808,771	1,702,785	2,603,899	517,404	244,031	393,013	23,940,278
<b>Scripts per Capita</b>	9.1	8.7	8.6	10.3	6.9	11.2	3	5.7	8.7
<b>Govt Cost per Capita</b>	\$349.28	\$337.19	\$329.63	\$358.04	\$270.21	\$419.68	\$121.00	\$261.61	\$332.04
<b>Population Percentage</b>	32.0%	25.0%	20.1%	7.1%	10.9%	2.2%	1.0%	1.6%	100.0%
<b>Scripts Percentage</b>	33.7%	25.0%	20.0%	8.4%	8.6%	2.8%	0.4%	1.1%	100.0%
<b>Govt Cost Percentage</b>	33.7%	25.4%	19.9%	7.7%	8.9%	2.7%	0.4%	1.3%	100.0%
<b>Total Cost Percentage</b>	33.6%	25.4%	19.9%	7.7%	9.0%	2.7%	0.4%	1.3%	100.0%

\* Population 31 December 2015, Source: ABS Publication 3101.0

**Table 6: PBS Prescription Volume, Government Cost and Average Government Cost / Script for 4 Financial Years.**

Section 85 only; excl. Drs Bag.

		Total	Total General	General Non-Safety Net	General Safety Net	Total Concessional	Concessional Non-Safety Net	Concessional Safety Net
<b>Script Volume</b>	2012-13	197,328,974	24,069,460	19,698,402	4,371,058	173,259,514	133,647,520	39,611,994
	2013-14	209,964,792	22,613,314	18,560,731	4,052,583	187,351,478	145,342,467	42,009,011
	2014-15	211,704,813	19,447,417	15,902,515	3,544,902	192,257,396	147,979,717	44,277,679
	2015-16	207,601,130	16,951,875	13,770,978	3,180,897	190,649,255	146,529,394	44,119,861
	Change*	-4,103,683	-2,495,542	-2,131,537	-364,005	-1,608,141	-1,450,323	-157,818
<b>Government Cost</b>	2012-13	\$7,088,662,996	\$1,517,311,133	\$1,347,926,501	\$169,384,632	\$5,571,351,863	\$4,219,815,465	\$1,351,536,398
	2013-14	\$7,317,674,872	\$1,595,250,414	\$1,440,335,710	\$154,914,704	\$5,722,424,458	\$4,333,840,916	\$1,388,583,542
	2014-15	\$7,096,679,044	\$1,592,780,575	\$1,463,256,600	\$129,523,975	\$5,503,898,470	\$4,123,482,128	\$1,380,416,342
	2015-16	\$7,949,018,254	\$1,904,179,793	\$1,785,357,915	\$118,821,879	\$6,044,838,460	\$4,630,980,302	\$1,413,858,158
	Change*	\$852,339,209	\$311,399,219	\$322,101,315	-\$10,702,096	\$540,939,990	\$507,498,174	\$33,441,816
<b>Average Govt Cost /</b>	2012-13	\$35.92	\$63.04	\$68.43	\$38.75	\$32.16	\$31.57	\$34.12
	2013-14	\$34.85	\$70.54	\$77.60	\$38.23	\$30.54	\$29.82	\$33.05
	2014-15	\$33.52	\$81.90	\$92.01	\$36.54	\$28.63	\$27.87	\$31.18
	2015-16	\$38.29	\$112.33	\$129.65	\$37.35	\$31.71	\$31.60	\$32.05
	Change*	\$4.77	\$30.43	\$37.63	\$0.82	\$3.08	\$3.74	\$0.87

<b>Percentage Differences</b>		Total	Total General	General Non-Safety Net	General Safety Net	Total Concessional	Concessional Non-Safety Net	Concessional Safety Net
<b>Script Volume</b>	Change*	-1.94%	-12.83%	-13.40%	-10.27%	-0.84%	-0.98%	-0.36%
<b>Government Cost</b>	Change*	12.01%	19.55%	22.01%	-8.26%	9.83%	12.31%	2.42%
<b>Average Govt Cost / Script</b>	Change*	14.22%	37.15%	40.90%	2.24%	10.75%	13.42%	2.79%

\* Change between the two most recent years.

**Table 7: ATC Main Group Comparison, 2014-15 and 2015-16.**  
Section 85 only; incl. Drs Bag.

ATC Group Level 1	2014-15				2015-16			
	Script Volume	Government Cost	Total Cost*	Ave. Price**	Script Volume	Government Cost	Total Cost*	Ave. Price**
Alimentary Tract And Metabolism	31,496,440	\$966,418,221	\$1,186,280,308	\$37.66	31,332,489	\$995,521,159	\$1,210,841,083	\$38.64
Blood And Blood Forming Organs	9,376,438	\$327,208,401	\$395,274,877	\$42.16	9,288,892	\$381,700,599	\$454,349,931	\$48.91
Cardiovascular System	67,007,923	\$1,208,100,274	\$1,625,140,889	\$24.25	65,087,112	\$1,072,564,436	\$1,448,210,513	\$22.25
Dermatologicals	3,077,535	\$65,388,807	\$95,561,030	\$31.05	2,958,275	\$69,260,892	\$97,480,793	\$32.95
Genito Urinary System And Sex Hormones	3,349,368	\$135,142,184	\$161,992,281	\$48.37	3,339,442	\$132,363,323	\$158,857,022	\$47.57
Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	3,488,010	\$64,072,196	\$83,044,263	\$23.81	3,523,977	\$64,166,577	\$83,645,239	\$23.74
Antiinfectives For Systemic Use	14,284,714	\$189,070,791	\$278,536,418	\$19.50	14,038,724	\$851,879,518	\$940,350,362	\$66.98
Antineoplastic And Immunomodulating Agents	2,191,482	\$1,497,208,766	\$1,535,977,434	\$700.89	2,347,366	\$1,670,783,199	\$1,712,545,981	\$729.56
Musculo-Skeletal System	8,195,614	\$268,378,694	\$317,974,368	\$38.80	7,801,645	\$274,807,371	\$321,931,011	\$41.26
Nervous System	48,675,964	\$1,348,642,453	\$1,680,364,805	\$34.52	47,673,460	\$1,344,823,211	\$1,647,780,750	\$34.56
Antiparasitic Products, Insecticides And Repellents	99,182	\$1,915,285	\$2,458,435	\$24.79	93,254	\$2,317,741	\$2,866,472	\$30.74
Respiratory System	11,850,853	\$482,355,451	\$605,483,604	\$51.09	11,856,413	\$459,275,517	\$584,193,432	\$49.27
Sensory Organs	8,269,820	\$470,244,818	\$515,774,700	\$62.37	7,920,127	\$570,921,248	\$615,189,405	\$77.67
Various	562,216	\$85,720,462	\$91,007,106	\$161.87	570,532	\$70,591,300	\$75,979,795	\$133.17
Not otherwise specified	159,630	\$3,152,276	\$4,052,838	\$25.39	158,281	\$3,929,313	\$4,888,753	\$30.89
<b>Total</b>	<b>212,085,189</b>	<b>\$7,113,019,081</b>	<b>\$8,578,923,354</b>	<b>\$40.45</b>	<b>207,989,989</b>	<b>\$7,964,905,404</b>	<b>\$9,359,110,541</b>	<b>\$45.00</b>

ATC Group Level 1	2014-15 to 2015-16 - Change in Number				2014-15 to 2015-16 - Change in Percentage			
	Script Change	Government Cost Change	Total Cost Change	Ave. Price Change	Script Change	Government Cost Change	Total Cost Change	Ave. Price Change
Alimentary Tract And Metabolism	-163,951	\$29,102,938	\$24,560,775	\$0.98	-0.52%	3.01%	2.07%	2.60%
Blood And Blood Forming Organs	-87,546	\$54,492,197	\$59,075,054	\$6.76	-0.93%	16.65%	14.95%	16.03%
Cardiovascular System	-1,920,811	-\$135,535,838	-\$176,930,377	-\$2.00	-2.87%	-11.22%	-10.89%	-8.26%
Dermatologicals	-119,260	\$3,872,085	\$1,919,763	\$1.90	-3.88%	5.92%	2.01%	6.12%
Genito Urinary System And Sex Hormones	-9,926	-\$2,778,861	-\$3,135,258	-\$0.80	-0.30%	-2.06%	-1.94%	-1.64%
Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	35,967	\$94,381	\$600,977	-\$0.07	1.03%	0.15%	0.72%	-0.30%
Antiinfectives For Systemic Use	-245,990	\$662,808,727	\$661,813,944	\$47.48	-1.72%	350.56%	237.60%	243.52%
Antineoplastic And Immunomodulating Agents	155,884	\$173,574,433	\$176,568,548	\$28.68	7.11%	11.59%	11.50%	4.09%
Musculo-Skeletal System	-393,969	\$6,428,676	\$3,956,643	\$2.47	-4.81%	2.40%	1.24%	6.36%
Nervous System	-1,002,504	-\$3,819,243	-\$32,584,055	\$0.04	-2.06%	-0.28%	-1.94%	0.12%
Antiparasitic Products, Insecticides And Repellents	-5,928	\$402,456	\$408,037	\$5.95	-5.98%	21.01%	16.60%	24.01%
Respiratory System	5,560	-\$23,079,934	-\$21,290,172	-\$1.82	0.05%	-4.78%	-3.52%	-3.56%
Sensory Organs	-349,693	\$100,676,430	\$99,414,705	\$15.31	-4.23%	21.41%	19.27%	24.54%
Various	8,316	-\$15,129,162	-\$15,027,311	-\$28.70	1.48%	-17.65%	-16.51%	-17.73%
Not otherwise specified	-1,349	\$777,037	\$835,915	\$5.50	-0.85%	24.65%	20.63%	21.65%
<b>Total</b>	<b>-4,095,200</b>	<b>\$851,886,323</b>	<b>\$780,187,187</b>	<b>\$4.55</b>	<b>-1.93%</b>	<b>11.98%</b>	<b>9.09%</b>	<b>11.24%</b>

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

**Table 8(a): Significant Drug Groups (ATC Level 2) by Highest Government Cost, 2014-15 and 2015-16.**  
Section 85 only; incl. Drs Bag.

Rank	ATC Group Level 2	Script Volume 2014-15	Government Cost 2014-15	Total Cost* 2014-15	Ave. Price** 2014-15	Script Volume 2015-16	Government Cost 2015-16	Total Cost* 2015-16	Ave. Price** 2015-16
1	Immunosuppressants	896,827	\$860,122,780	\$878,926,831	\$980.04	1,013,225	\$956,522,834	\$977,792,081	\$965.03
2	Antivirals For Systemic Use	755,103	\$47,336,797	\$66,727,388	\$88.37	741,542	\$677,290,929	\$695,338,557	\$937.69
3	Ophthalmologicals	7,607,472	\$466,833,499	\$509,289,084	\$66.95	7,265,279	\$565,579,385	\$606,765,779	\$83.52
4	Analgesics	20,409,274	\$476,362,358	\$589,538,533	\$28.89	20,025,519	\$525,054,534	\$638,787,171	\$31.90
5	Drugs Used In Diabetes	9,097,012	\$498,921,307	\$573,152,219	\$63.00	9,607,366	\$518,792,721	\$603,710,525	\$62.84
6	Lipid Modifying Agents	23,132,724	\$633,220,137	\$825,312,818	\$35.68	21,918,722	\$471,941,158	\$624,913,212	\$28.51
7	Drugs For Obstructive Airway Diseases	11,654,085	\$479,079,073	\$601,260,159	\$51.59	11,665,730	\$455,336,307	\$579,272,102	\$49.66
8	Antineoplastic Agents	452,475	\$355,143,900	\$362,003,316	\$800.05	487,161	\$411,276,158	\$418,945,411	\$859.97
9	Antithrombotic Agents	8,342,550	\$293,776,268	\$354,561,981	\$42.50	8,348,653	\$330,660,333	\$395,645,325	\$47.39
10	Agents Acting On The Renin-Angiotensin System	23,756,351	\$331,554,624	\$456,642,046	\$19.22	23,515,943	\$325,332,401	\$451,404,011	\$19.20
11	Psycholeptics	8,164,091	\$327,361,896	\$376,639,978	\$46.13	7,904,740	\$288,342,622	\$334,786,296	\$42.35
12	Drugs For Acid Related Disorders	17,080,355	\$285,560,059	\$393,200,339	\$23.02	16,630,973	\$282,806,894	\$374,615,891	\$22.53
13	Psychoanaleptics	16,037,880	\$269,058,215	\$393,471,573	\$24.53	15,758,704	\$261,567,063	\$364,312,278	\$23.12
14	Endocrine Therapy	777,138	\$217,693,756	\$229,342,001	\$295.11	783,048	\$241,868,925	\$253,243,757	\$323.41
15	Drugs For Treatment Of Bone Diseases	2,754,007	\$198,228,133	\$222,049,246	\$80.63	2,433,569	\$200,591,959	\$221,956,186	\$91.21
16	Antibacterials For Systemic Use	13,417,569	\$103,919,238	\$172,844,411	\$12.88	13,175,415	\$135,972,926	\$205,189,010	\$15.57
17	Other Nervous System Drugs	637,500	\$110,049,644	\$122,407,617	\$192.01	633,797	\$105,582,523	\$117,702,638	\$185.71

Rank	ATC Group Level 2	2014-15 to 2015-16 - Change in Number				2014-15 to 2015-16 - Change in Percentage			
		Script Change	Government Cost Change	Total Cost Change	Ave. Price Change	Script Change	Government Cost Change	Total Cost Change	Ave. Price Change
1	Immunosuppressants	116,398	\$96,400,054	\$98,865,250	-\$15.01	12.98%	11.21%	11.25%	-1.53%
2	Antivirals For Systemic Use	-13,561	\$629,954,132	\$628,611,169	\$849.32	-1.80%	1330.79%	942.06%	961.12%
3	Ophthalmologicals	-342,193	\$98,745,886	\$97,476,695	\$16.57	-4.50%	21.15%	19.14%	24.75%
4	Analgesics	-383,755	\$48,692,175	\$49,248,637	\$3.01	-1.88%	10.22%	8.35%	10.43%
5	Drugs Used In Diabetes	510,354	\$19,871,414	\$30,558,306	-\$0.17	5.61%	3.98%	5.33%	-0.26%
6	Lipid Modifying Agents	-1,214,002	-\$161,278,980	-\$200,399,606	-\$7.17	-5.25%	-25.47%	-24.28%	-20.09%
7	Drugs For Obstructive Airway Diseases	11,645	-\$23,742,766	-\$21,988,057	-\$1.94	0.10%	-4.96%	-3.66%	-3.75%
8	Antineoplastic Agents	34,686	\$56,132,259	\$56,942,094	\$59.92	7.67%	15.81%	15.73%	7.49%
9	Antithrombotic Agents	6,103	\$36,884,065	\$41,083,344	\$4.89	0.07%	12.56%	11.59%	11.51%
10	Agents Acting On The Renin-Angiotensin System	-240,408	-\$6,222,223	-\$5,238,035	-\$0.03	-1.01%	-1.88%	-1.15%	-0.14%
11	Psycholeptics	-259,351	-\$39,019,275	-\$41,853,682	-\$3.78	-3.18%	-11.92%	-11.11%	-8.20%
12	Drugs For Acid Related Disorders	-449,382	-\$2,753,165	-\$18,584,448	-\$0.50	-2.63%	-0.96%	-4.73%	-2.15%
13	Psychoanaleptics	-279,176	-\$7,491,152	-\$29,159,294	-\$1.42	-1.74%	-2.78%	-7.41%	-5.77%
14	Endocrine Therapy	5,910	\$24,175,169	\$23,901,756	\$28.30	0.76%	11.11%	10.42%	9.59%
15	Drugs For Treatment Of Bone Diseases	-320,438	\$2,363,826	-\$93,060	\$10.58	-11.64%	1.19%	-0.04%	13.12%
16	Antibacterials For Systemic Use	-242,154	\$32,053,688	\$32,344,599	\$2.69	-1.80%	30.84%	18.71%	20.89%
17	Other Nervous System Drugs	-3,703	-\$4,467,121	-\$4,704,980	-\$6.30	-0.58%	-4.06%	-3.84%	-3.28%

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

Table 8(b): Significant Drug Groups (ATC Level 2) by Highest Script Volume, 2014-15 and 2015-16.  
Section 85 only; incl. Drs Bag.

Rank	ATC Group Level 2	Script Volume 2014-15	Government Cost 2014-15	Total Cost* 2014-15	Ave. Price** 2014-15	Script Volume 2015-16	Government Cost 2015-16	Total Cost* 2015-16	Ave. Price** 2015-16
1	Agents Acting On The Renin-Angiotensin System	23,756,351	\$331,554,624	\$456,642,046	\$19.22	23,515,943	\$325,332,401	\$451,404,011	\$19.20
2	Lipid Modifying Agents	23,132,724	\$633,220,137	\$825,312,818	\$35.68	21,918,722	\$471,941,158	\$624,913,212	\$28.51
3	Analgesics	20,409,274	\$476,362,358	\$589,538,533	\$28.89	20,025,519	\$525,054,534	\$638,787,171	\$31.90
4	Drugs For Acid Related Disorders	17,080,355	\$285,560,059	\$393,200,339	\$23.02	16,630,973	\$282,806,894	\$374,615,891	\$22.53
5	Psychoanaleptics	16,037,880	\$269,058,215	\$393,471,573	\$24.53	15,758,704	\$261,567,063	\$364,312,278	\$23.12
6	Antibacterials For Systemic Use	13,417,569	\$103,919,238	\$172,844,411	\$12.88	13,175,415	\$135,972,926	\$205,189,010	\$15.57
7	Drugs For Obstructive Airway Diseases	11,654,085	\$479,079,073	\$601,260,159	\$51.59	11,665,730	\$455,336,307	\$579,272,102	\$49.66
8	Drugs Used In Diabetes	9,097,012	\$498,921,307	\$573,152,219	\$63.00	9,607,366	\$518,792,721	\$603,710,525	\$62.84
9	Antithrombotic Agents	8,342,550	\$293,776,268	\$354,561,981	\$42.50	8,348,653	\$330,660,333	\$395,645,325	\$47.39
10	Psycholeptics	8,164,091	\$327,361,896	\$376,639,978	\$46.13	7,904,740	\$288,342,622	\$334,786,296	\$42.35
11	Ophthalmologicals	7,607,472	\$466,833,499	\$509,289,084	\$66.95	7,265,279	\$565,579,385	\$606,765,779	\$83.52
12	Calcium Channel Blockers	6,762,495	\$54,182,598	\$85,527,494	\$12.65	6,526,167	\$66,919,104	\$97,767,993	\$14.98
13	Beta Blocking Agents	6,311,742	\$74,032,903	\$107,046,382	\$16.96	6,218,726	\$82,483,949	\$113,678,145	\$18.28
14	Antiinflammatory And Antirheumatic Products	4,138,191	\$57,945,941	\$77,649,311	\$18.76	4,046,907	\$58,575,089	\$78,106,556	\$19.30
15	Cardiac Therapy	3,169,820	\$63,881,909	\$82,725,963	\$26.10	3,049,304	\$65,478,862	\$83,191,568	\$27.28
16	Drugs For Treatment Of Bone Diseases	2,754,007	\$198,228,133	\$222,049,246	\$80.63	2,433,569	\$200,591,959	\$221,956,186	\$91.21
17	Diuretics	2,363,434	\$20,742,852	\$30,542,053	\$12.92	2,350,085	\$26,881,592	\$36,846,268	\$15.68

Rank	ATC Group Level 2	2014-15 to 2015-16 - Change in Number				2014-15 to 2015-16 - Change in Percentage			
		Script Change	Government Cost Change	Total Cost Change	Ave. Price Change	Script Change	Government Cost Change	Total Cost Change	Ave. Price Change
1	Agents Acting On The Renin-Angiotensin System	-240,408	-\$6,222,223	-\$5,238,035	-\$0.03	-1.01%	-1.88%	-1.15%	-0.14%
2	Lipid Modifying Agents	-1,214,002	-\$161,278,980	-\$200,399,606	-\$7.17	-5.25%	-25.47%	-24.28%	-20.09%
3	Analgesics	-383,755	\$48,692,175	\$49,248,637	\$3.01	-1.88%	10.22%	8.35%	10.43%
4	Drugs For Acid Related Disorders	-449,382	-\$2,753,165	-\$18,584,448	-\$0.50	-2.63%	-0.96%	-4.73%	-2.15%
5	Psychoanaleptics	-279,176	-\$7,491,152	-\$29,159,294	-\$1.42	-1.74%	-2.78%	-7.41%	-5.77%
6	Antibacterials For Systemic Use	-242,154	\$32,053,688	\$32,344,599	\$2.69	-1.80%	30.84%	18.71%	20.89%
7	Drugs For Obstructive Airway Diseases	11,645	-\$23,742,766	-\$21,988,057	-\$1.94	0.10%	-4.96%	-3.66%	-3.75%
8	Drugs Used In Diabetes	510,354	\$19,871,414	\$30,558,306	-\$0.17	5.61%	3.98%	5.33%	-0.26%
9	Antithrombotic Agents	6,103	\$36,884,065	\$41,083,344	\$4.89	0.07%	12.56%	11.59%	11.51%
10	Psycholeptics	-259,351	-\$39,019,275	-\$41,853,682	-\$3.78	-3.18%	-11.92%	-11.11%	-8.20%
11	Ophthalmologicals	-342,193	\$98,745,886	\$97,476,695	\$16.57	-4.50%	21.15%	19.14%	24.75%
12	Calcium Channel Blockers	-236,328	\$12,736,505	\$12,240,499	\$2.33	-3.49%	23.51%	14.31%	18.45%
13	Beta Blocking Agents	-93,016	\$8,451,047	\$6,631,763	\$1.32	-1.47%	11.42%	6.20%	7.78%
14	Antiinflammatory And Antirheumatic Products	-91,284	\$457,248	\$457,246	\$0.54	-2.21%	1.09%	0.59%	2.86%
15	Cardiac Therapy	-120,516	\$1,596,953	\$465,605	\$1.18	-3.80%	2.50%	0.56%	4.54%
16	Drugs For Treatment Of Bone Diseases	-320,438	\$2,363,826	-\$93,060	\$10.58	-11.64%	1.19%	-0.04%	13.12%
17	Diuretics	-13,349	\$6,138,741	\$6,304,216	\$2.76	-0.56%	29.59%	20.64%	21.33%

\* Total Cost includes cost to the patient and cost to the government

\*\* Average Price is Total Cost divided by Script Volume.

Table 9(a): Significant Drugs Sorted by Highest Change to Government Cost, 2014-15 and 2015-16.

Section 85 only; incl. Drs Bag.

Rank	Drug	Script Volume 2014-15	Government Cost 2014-15	Total Cost* 2014-15	Ave. Price** 2014-15	Script Volume 2015-16	Government Cost 2015-16	Total Cost* 2015-16	Ave. Price** 2015-16	Government Cost Change	Government Cost Change Percentage
1	Ledipasvir + Sofosbuvir	0	\$0	\$0	\$0.00	15,776	\$357,875,840	\$358,203,581	\$22,705.60	<b>\$357,875,840</b>	.
2	Sofosbuvir	0	\$0	\$0	\$0.00	10,702	\$213,273,366	\$213,465,013	\$19,946.27	<b>\$213,273,366</b>	.
3	Daclatasvir	0	\$0	\$0	\$0.00	9,918	\$79,114,622	\$79,291,724	\$7,994.73	<b>\$79,114,622</b>	.
4	Ranibizumab	102,395	\$157,805,783	\$158,845,494	\$1,551.30	146,736	\$217,812,843	\$219,604,664	\$1,496.60	<b>\$60,007,060</b>	38.03%
5	Enzalutamide	3,834	\$14,253,932	\$14,295,209	\$3,728.54	14,314	\$53,224,804	\$53,367,373	\$3,728.33	<b>\$38,970,871</b>	273.40%
6	Aflibercept	111,892	\$174,926,226	\$176,174,586	\$1,574.51	142,372	\$213,134,445	\$214,882,554	\$1,509.30	<b>\$38,208,219</b>	21.84%
7	Trametinib	0	\$0	\$0	\$0.00	4,306	\$37,956,357	\$38,041,950	\$8,834.64	<b>\$37,956,357</b>	.
8	Apixaban	326,062	\$29,591,346	\$32,943,136	\$101.03	684,974	\$58,715,164	\$65,981,380	\$96.33	<b>\$29,123,818</b>	98.42%
9	Denosumab	287,554	\$93,779,218	\$96,892,489	\$336.95	403,366	\$121,961,712	\$126,361,836	\$313.27	<b>\$28,182,494</b>	30.05%
10	Pregabalin	2,525,250	\$114,272,927	\$140,537,368	\$55.65	3,150,492	\$139,093,159	\$171,497,777	\$54.44	<b>\$24,820,232</b>	21.72%
11	Adalimumab	176,657	\$312,982,849	\$317,299,681	\$1,796.13	193,120	\$334,694,252	\$339,560,312	\$1,758.29	<b>\$21,711,403</b>	6.94%
12	Rivaroxaban	917,572	\$75,613,312	\$87,117,140	\$94.94	1,246,539	\$96,288,227	\$112,155,727	\$89.97	<b>\$20,674,915</b>	27.34%
13	Tofacitinib	0	\$0	\$0	\$0.00	9,525	\$16,607,441	\$16,790,076	\$1,762.74	<b>\$16,607,441</b>	.
14	Iron	67,434	\$18,747,326	\$20,220,150	\$299.85	123,597	\$33,858,891	\$36,577,546	\$295.94	<b>\$15,111,565</b>	80.61%
15	Oxycodone + Naloxone	1,241,036	\$48,623,056	\$57,051,182	\$45.97	1,538,559	\$60,182,190	\$70,778,979	\$46.00	<b>\$11,559,135</b>	23.77%
16	Secukinumab	0	\$0	\$0	\$0.00	6,563	\$11,320,378	\$11,510,411	\$1,753.83	<b>\$11,320,378</b>	.
17	Dapagliflozin	123,918	\$6,300,377	\$8,457,924	\$68.25	426,383	\$17,452,332	\$24,550,508	\$57.58	<b>\$11,151,955</b>	177.00%
18	Ruxolitinib	0	\$0	\$0	\$0.00	2,145	\$10,309,731	\$10,340,556	\$4,820.77	<b>\$10,309,731</b>	.
19	Aripiprazole	193,431	\$40,918,209	\$43,157,343	\$223.11	240,722	\$51,061,641	\$53,889,273	\$223.87	<b>\$10,143,432</b>	24.79%
20	Paracetamol + Codeine	2,350,284	\$11,948,314	\$22,692,628	\$9.66	2,277,953	\$22,081,214	\$32,665,527	\$14.34	<b>\$10,132,900</b>	84.81%
21	Ezetimibe + Atorvastatin	0	\$0	\$0	\$0.00	177,958	\$10,110,125	\$13,089,792	\$73.56	<b>\$10,110,125</b>	.
22	Rosuvastatin (&) Ezetimibe	18,551	\$1,176,012	\$1,530,417	\$82.50	192,662	\$10,964,262	\$14,556,245	\$75.55	<b>\$9,788,250</b>	832.33%
23	Indacaterol + Glycopyrronium	36,585	\$3,176,560	\$3,513,639	\$96.04	148,166	\$12,401,726	\$13,634,672	\$92.02	<b>\$9,225,166</b>	290.41%
24	Fingolimod	60,431	\$138,353,395	\$139,821,110	\$2,313.73	64,468	\$147,542,266	\$149,158,012	\$2,313.68	<b>\$9,188,871</b>	6.64%
25	Pantoprazole	4,385,926	\$37,134,654	\$57,357,742	\$13.08	4,586,606	\$46,169,367	\$67,713,300	\$14.76	<b>\$9,034,713</b>	24.33%
26	Fluticasone + Vilanterol	25,811	\$1,287,461	\$1,690,940	\$65.51	200,176	\$9,828,725	\$12,817,744	\$64.03	<b>\$8,541,264</b>	663.42%
27	Cephalexin	2,820,866	\$11,567,624	\$25,512,178	\$9.04	2,796,175	\$20,041,190	\$34,145,472	\$12.21	<b>\$8,473,566</b>	73.25%
28	Mycophenolate	24,552	\$7,070,083	\$7,475,516	\$304.48	72,403	\$15,397,734	\$16,677,970	\$230.35	<b>\$8,327,651</b>	117.79%
29	Atenolol	2,718,956	\$10,311,014	\$23,067,419	\$8.48	2,580,430	\$18,203,774	\$30,521,804	\$11.83	<b>\$7,892,759</b>	76.55%
30	Tramadol	1,942,654	\$15,581,320	\$23,846,638	\$12.28	1,955,057	\$23,373,197	\$31,986,050	\$16.36	<b>\$7,791,877</b>	50.01%
31	Ustekinumab	8,627	\$53,376,731	\$53,620,150	\$6,215.39	10,015	\$60,964,386	\$61,252,245	\$6,116.05	<b>\$7,587,655</b>	14.22%
32	Metformin	3,617,132	\$29,121,744	\$44,635,405	\$12.34	3,553,833	\$36,580,541	\$52,050,511	\$14.65	<b>\$7,458,798</b>	25.61%
33	Amoxicillin	2,461,805	\$9,360,887	\$22,328,234	\$9.07	2,366,406	\$16,313,297	\$28,951,065	\$12.23	<b>\$6,952,410</b>	74.27%
34	Crizotinib	0	\$0	\$0	\$0.00	917	\$6,916,085	\$6,937,894	\$7,565.86	<b>\$6,916,085</b>	.
35	Levodopa + Carbidopa Anhydrous	284,381	\$23,104,073	\$25,543,729	\$89.82	277,784	\$29,937,206	\$32,055,540	\$115.40	<b>\$6,833,134</b>	29.58%

\* Total Cost includes cost to the patient and cost to the government

\*\* Average Price is Total Cost divided by Script Volume.

Table 9(b): Significant Drugs Sorted by Highest Change to Script Volume, 2014-15 and 2015-16.

Section 85 only; incl. Drs Bag.

Rank	Drug	Script Volume 2014-15	Government Cost 2014-15	Total Cost* 2014-15	Ave. Price** 2014-15	Script Volume 2015-16	Government Cost 2015-16	Total Cost* 2015-16	Ave. Price** 2015-16	Script Volume Change	Script Volume Change Percentage
1	Pregabalin	2,525,250	\$114,272,927	\$140,537,368	\$55.65	3,150,492	\$139,093,159	\$171,497,777	\$54.44	625,242	24.76%
2	Apixaban	326,062	\$29,591,346	\$32,943,136	\$101.03	684,974	\$58,715,164	\$65,981,380	\$96.33	358,912	110.07%
3	Rivaroxaban	917,572	\$75,613,312	\$87,117,140	\$94.94	1,246,539	\$96,288,227	\$112,155,727	\$89.97	328,967	35.85%
4	Dapagliflozin	123,918	\$6,300,377	\$8,457,924	\$68.25	426,383	\$17,452,332	\$24,550,508	\$57.58	302,465	244.08%
5	Oxycodone + Naloxone	1,241,036	\$48,623,056	\$57,051,182	\$45.97	1,538,559	\$60,182,190	\$70,778,979	\$46.00	297,523	23.97%
6	Pantoprazole	4,385,926	\$37,134,654	\$57,357,742	\$13.08	4,586,606	\$46,169,367	\$67,713,300	\$14.76	200,680	4.58%
7	Ezetimibe + Atorvastatin	0	\$0	\$0	\$0.00	177,958	\$10,110,125	\$13,089,792	\$73.56	177,958	.
8	Sitagliptin + Metformin	813,293	\$38,496,373	\$51,184,869	\$62.94	989,809	\$44,248,114	\$60,018,554	\$60.64	176,516	21.70%
9	Fluticasone + Vilanterol	25,811	\$1,287,461	\$1,690,940	\$65.51	200,176	\$9,828,725	\$12,817,744	\$64.03	174,365	675.55%
10	Rosuvastatin (&) Ezetimibe	18,551	\$1,176,012	\$1,530,417	\$82.50	192,662	\$10,964,262	\$14,556,245	\$75.55	174,111	938.55%
11	Tapentadol	111,221	\$3,404,442	\$4,319,994	\$38.84	269,767	\$9,116,532	\$11,453,372	\$42.46	158,546	142.55%
12	Perindopril + Amlodipine	1,255,878	\$30,613,455	\$44,445,870	\$35.39	1,402,630	\$33,232,602	\$48,315,128	\$34.45	146,752	11.69%
13	Denosumab	287,554	\$93,779,218	\$96,892,489	\$336.95	403,366	\$121,961,712	\$126,361,836	\$313.27	115,812	40.27%
14	Indacaterol + Glycopyrronium	36,585	\$3,176,560	\$3,513,639	\$96.04	148,166	\$12,401,726	\$13,634,672	\$92.02	111,581	304.99%
15	Dutasteride + Tamsulosin	451,890	\$13,954,861	\$16,048,368	\$35.51	552,971	\$16,846,464	\$19,454,867	\$35.18	101,081	22.37%
16	Mirtazapine	1,507,376	\$16,258,778	\$23,232,650	\$15.41	1,606,123	\$18,923,574	\$26,456,595	\$16.47	98,747	6.55%
17	Escitalopram	1,607,337	\$12,511,521	\$20,610,483	\$12.82	1,701,964	\$15,753,319	\$24,469,989	\$14.38	94,627	5.89%
18	Telmisartan + Amlodipine	453,277	\$8,467,218	\$10,832,195	\$23.90	529,226	\$9,850,540	\$12,656,520	\$23.92	75,949	16.76%
19	Olmесartan Medoxomil	530,088	\$8,261,943	\$11,021,217	\$20.79	599,007	\$10,261,906	\$13,433,682	\$22.43	68,919	13.00%
20	Empagliflozin	1,349	\$62,784	\$86,872	\$64.40	61,572	\$2,707,158	\$3,750,102	\$60.91	60,223	4464.27%
21	Linagliptin + Metformin	56,985	\$2,916,372	\$3,792,334	\$66.55	117,169	\$5,777,742	\$7,565,820	\$64.57	60,184	105.61%
22	Doxycycline	921,292	\$3,793,498	\$8,132,112	\$8.83	980,296	\$6,964,274	\$11,693,598	\$11.93	59,004	6.40%
23	Lisdexamfetamine	0	\$0	\$0	\$0.00	58,540	\$5,682,437	\$6,822,414	\$116.54	58,540	.
24	Olmесartan + Amlodipine + Hydrochlorothiazide	60,901	\$1,528,094	\$1,839,264	\$30.20	118,527	\$2,974,523	\$3,588,871	\$30.28	57,626	94.62%
25	Iron	67,434	\$18,747,326	\$20,220,150	\$299.85	123,597	\$33,858,891	\$36,577,546	\$295.94	56,163	83.29%
26	Acidinium	41,185	\$2,235,911	\$2,581,642	\$62.68	96,337	\$5,107,699	\$5,908,309	\$61.33	55,152	133.91%
27	Macrogol-3350 + Sodium Chloride + Bicarbonate + Potassium Chloride	1,134,009	\$19,347,548	\$23,954,973	\$21.12	1,188,487	\$20,406,162	\$25,287,064	\$21.28	54,478	4.80%
28	Fenofibrate	990,749	\$26,647,647	\$40,710,035	\$41.09	1,044,026	\$27,004,276	\$41,792,529	\$40.03	53,277	5.38%
29	Olmесartan Medoxomil + Amlodipine	208,069	\$4,256,018	\$5,349,858	\$25.71	258,545	\$5,432,802	\$6,813,955	\$26.36	50,476	24.26%
30	Mycophenolate	24,552	\$7,070,083	\$7,475,516	\$304.48	72,403	\$15,397,734	\$16,677,970	\$230.35	47,851	194.90%
31	Aripiprazole	193,431	\$40,918,209	\$43,157,343	\$223.11	240,722	\$51,061,641	\$53,889,273	\$223.87	47,291	24.45%
32	Ticagrelor	145,422	\$18,892,812	\$21,594,219	\$148.49	191,918	\$23,304,721	\$26,900,745	\$140.17	46,496	31.97%
33	Fluoxetine	822,177	\$8,897,794	\$13,137,089	\$15.98	868,667	\$11,304,370	\$16,082,511	\$18.51	46,490	5.65%
34	Nebivolol	171,258	\$8,956,748	\$10,430,403	\$60.90	215,880	\$10,847,129	\$12,827,277	\$59.42	44,622	26.06%
35	Budesonide + Eformoterol	1,784,718	\$92,351,264	\$122,718,785	\$68.76	1,829,094	\$90,950,660	\$122,663,679	\$67.06	44,376	2.49%

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

**Table 10(a): PBS Drugs (Generic Name) Sorted by Highest Government Cost, 2015-16.**

Section 85 only; incl. Drs Bag.

Rank	Drug	Script Volume	Government Cost	Total Cost*	Ave. Price**
1	Ledipasvir + Sofosbuvir	15,776	\$357,875,840	\$358,203,581	\$22,705.60
2	Adalimumab	193,120	\$334,694,252	\$339,560,312	\$1,758.29
3	Ranibizumab	146,736	\$217,812,843	\$219,604,664	\$1,496.60
4	Sofosbuvir	10,702	\$213,273,366	\$213,465,013	\$19,946.27
5	Aflibercept	142,372	\$213,134,445	\$214,882,554	\$1,509.30
6	Esomeprazole	6,747,706	\$166,509,203	\$210,238,799	\$31.16
7	Etanercept	95,884	\$164,684,806	\$166,777,684	\$1,739.37
8	Fluticasone + Salmeterol	3,006,437	\$148,510,188	\$194,793,783	\$64.79
9	Fingolimod	64,468	\$147,542,266	\$149,158,012	\$2,313.68
10	Insulin Glargine	366,896	\$146,557,692	\$151,574,150	\$413.13
11	Pregabalin	3,150,492	\$139,093,159	\$171,497,777	\$54.44
12	Rosuvastatin	6,465,792	\$136,915,124	\$172,331,151	\$26.65
13	Denosumab	403,366	\$121,961,712	\$126,361,836	\$313.27
14	Imatinib	26,570	\$98,153,433	\$98,668,809	\$3,713.54
15	Rivaroxaban	1,246,539	\$96,288,227	\$112,155,727	\$89.97
16	Tiotropium	1,786,709	\$94,597,554	\$108,689,695	\$60.83
17	Budesonide + Eformoterol	1,829,094	\$90,950,660	\$122,663,679	\$67.06
18	Atorvastatin	7,490,700	\$85,103,958	\$121,514,059	\$16.22
19	Daclatasvir	9,918	\$79,114,622	\$79,291,724	\$7,994.73
20	Golimumab	45,576	\$76,256,407	\$77,350,463	\$1,697.18
21	Mesalazine	307,755	\$72,820,925	\$80,710,166	\$262.25
22	Paracetamol	4,946,779	\$67,940,241	\$84,110,948	\$17.00
23	Ezetimibe	1,195,215	\$66,290,405	\$82,103,658	\$68.69
24	Oxycodone	2,469,309	\$64,111,245	\$77,654,324	\$31.45
25	Buprenorphine	1,331,479	\$61,653,675	\$69,913,431	\$52.51
26	Ustekinumab	10,015	\$60,964,386	\$61,252,245	\$6,116.05
27	Oxycodone + Naloxone	1,538,559	\$60,182,190	\$70,778,979	\$46.00
28	Paliperidone	184,174	\$59,304,594	\$61,118,150	\$331.85
29	Apixaban	684,974	\$58,715,164	\$65,981,380	\$96.33
30	Ezetimibe + Simvastatin	988,150	\$58,002,711	\$71,550,249	\$72.41
31	Goserelin	73,398	\$57,601,690	\$58,798,451	\$801.09
32	Insulin Aspart	259,466	\$57,518,364	\$62,015,428	\$239.01
33	Enzalutamide	14,314	\$53,224,804	\$53,367,373	\$3,728.33
34	Aripiprazole	240,722	\$51,061,641	\$53,889,273	\$223.87
35	Insulin Aspart + Insulin Aspart Protamine	203,122	\$47,813,534	\$50,013,088	\$246.22
36	Dabrafenib	5,368	\$46,872,752	\$46,978,641	\$8,751.61
37	Quetiapine	930,374	\$46,819,768	\$55,352,226	\$59.49
38	Dimethyl Fumarate	25,832	\$46,506,098	\$47,168,327	\$1,825.96
39	Desvenlafaxine	1,464,961	\$46,464,344	\$65,913,523	\$44.99
40	Pantoprazole	4,586,606	\$46,169,367	\$67,713,300	\$14.76
41	Sitagliptin + Metformin	989,809	\$44,248,114	\$60,018,554	\$60.64
42	Leuprorelin	35,824	\$43,871,422	\$44,248,117	\$1,235.15
43	Enoxaparin Sodium	424,325	\$41,282,940	\$49,076,743	\$115.66
44	Dasatinib	8,122	\$41,168,015	\$41,362,674	\$5,092.67
45	Risperidone	579,954	\$40,840,455	\$44,313,128	\$76.41
46	Amlodipine + Atorvastatin	998,985	\$40,631,831	\$53,484,850	\$53.54
47	Perindopril	3,956,980	\$40,628,901	\$60,281,624	\$15.23
48	Salbutamol	2,953,779	\$38,394,642	\$50,759,290	\$17.18
49	Abiraterone	10,558	\$38,277,581	\$38,374,659	\$3,634.65
50	Trametinib	4,306	\$37,956,357	\$38,041,950	\$8,834.64

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

**Table 10(b): PBS Drugs (Generic Name) Sorted by Highest Script Volume, 2015-16.**

Section 85 only; incl. Drs Bag.

Rank	Drug	Script Volume	Government Cost	Total Cost*	Ave. Price**
1	Atorvastatin	7,490,700	\$85,103,958	\$121,514,059	\$16.22
2	Esomeprazole	6,747,706	\$166,509,203	\$210,238,799	\$31.16
3	Rosuvastatin	6,465,792	\$136,915,124	\$172,331,151	\$26.65
4	Paracetamol	4,946,779	\$67,940,241	\$84,110,948	\$17.00
5	Pantoprazole	4,586,606	\$46,169,367	\$67,713,300	\$14.76
6	Perindopril	3,956,980	\$40,628,901	\$60,281,624	\$15.23
7	Metformin	3,553,833	\$36,580,541	\$52,050,511	\$14.65
8	Pregabalin	3,150,492	\$139,093,159	\$171,497,777	\$54.44
9	Fluticasone + Salmeterol	3,006,437	\$148,510,188	\$194,793,783	\$64.79
10	Salbutamol	2,953,779	\$38,394,642	\$50,759,290	\$17.18
11	Irbesartan	2,854,173	\$29,783,417	\$43,880,367	\$15.37
12	Cephalexin	2,796,175	\$20,041,190	\$34,145,472	\$12.21
13	Atenolol	2,580,430	\$18,203,774	\$30,521,804	\$11.83
14	Simvastatin	2,485,415	\$20,969,872	\$32,855,407	\$13.22
15	Oxycodone	2,469,309	\$64,111,245	\$77,654,324	\$31.45
16	Amoxicillin	2,366,406	\$16,313,297	\$28,951,065	\$12.23
17	Amlodipine	2,287,286	\$16,173,441	\$27,152,530	\$11.87
18	Paracetamol + Codeine	2,277,953	\$22,081,214	\$32,665,527	\$14.34
19	Amoxicillin + Clavulanic Acid	2,245,060	\$18,405,551	\$29,740,753	\$13.25
20	Ramipril	2,219,371	\$19,175,276	\$29,882,996	\$13.46
21	Candesartan	2,046,936	\$23,971,337	\$34,225,764	\$16.72
22	Telmisartan	2,041,927	\$27,509,656	\$37,963,044	\$18.59
23	Warfarin	1,968,998	\$22,812,769	\$31,135,714	\$15.81
24	Tramadol	1,955,057	\$23,373,197	\$31,986,050	\$16.36
25	Irbesartan + Hydrochlorothiazide	1,936,369	\$26,203,527	\$35,889,983	\$18.53
26	Rabeprazole	1,928,722	\$24,987,762	\$34,254,815	\$17.76
27	Clopidogrel	1,900,880	\$25,260,627	\$33,633,724	\$17.69
28	Sertraline	1,887,189	\$15,494,802	\$24,935,314	\$13.21
29	Budesonide + Eformoterol	1,829,094	\$90,950,660	\$122,663,679	\$67.06
30	Tiotropium	1,786,709	\$94,597,554	\$108,689,695	\$60.83
31	Omeprazole	1,778,603	\$22,472,411	\$30,876,378	\$17.36
32	Diazepam	1,768,171	\$11,330,699	\$19,783,053	\$11.19
33	Venlafaxine	1,721,646	\$25,566,056	\$35,087,290	\$20.38
34	Escitalopram	1,701,964	\$15,753,319	\$24,469,989	\$14.38
35	Lercanidipine	1,678,257	\$15,373,108	\$23,249,278	\$13.85
36	Metoprolol Tartrate	1,672,150	\$13,384,359	\$20,916,519	\$12.51
37	Mirtazapine	1,606,123	\$18,923,574	\$26,456,595	\$16.47
38	Oxycodone + Naloxone	1,538,559	\$60,182,190	\$70,778,979	\$46.00
39	Temazepam	1,508,526	\$9,813,620	\$16,559,466	\$10.98
40	Meloxicam	1,498,384	\$15,823,370	\$22,943,331	\$15.31
41	Amitriptyline	1,470,197	\$12,978,683	\$19,597,094	\$13.33
42	Fruzemide	1,466,595	\$11,121,631	\$16,887,352	\$11.51
43	Desvenlafaxine	1,464,961	\$46,464,344	\$65,913,523	\$44.99
44	Gliclazide	1,405,115	\$18,289,499	\$24,137,131	\$17.18
45	Perindopril + Amlodipine	1,402,630	\$33,232,602	\$48,315,128	\$34.45
46	Buprenorphine	1,331,479	\$61,653,675	\$69,913,431	\$52.51
47	Rivaroxaban	1,246,539	\$96,288,227	\$112,155,727	\$89.97
48	Prednisolone	1,246,019	\$9,676,191	\$15,325,577	\$12.30
49	Ezetimibe	1,195,215	\$66,290,405	\$82,103,658	\$68.69
50	Macrogol-3350 + Sodium Chloride + Bicarbonate + Potassium Chloride	1,188,487	\$20,406,162	\$25,287,064	\$21.28

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

Table 11(a): PBS Items Sorted by Highest Government Cost, 2015-16.  
Section 85 only; incl. Drs Bag.

Rank	Item Code	Drug	Form	Script Volume	Government Cost	Total Cost*	Ave. Price**
1	10628J	Ledipasvir + Sofosbuvir	Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir	11,590	\$262,808,689	\$263,051,979	\$22,696.46
2	02168D	Aflibercept	Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)	132,069	\$195,398,587	\$196,939,570	\$1,491.19
3	10138N	Ranibizumab	Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe	106,654	\$154,182,838	\$155,400,087	\$1,457.05
4	05262Y	Fingolimod	Capsule 500 micrograms (as hydrochloride)	64,468	\$147,542,266	\$149,158,012	\$2,313.68
5	09039R	Insulin Glargine	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	366,896	\$146,557,692	\$151,574,150	\$413.13
6	10624E	Sofosbuvir	Tablet 400 mg	6,425	\$127,693,261	\$127,810,562	\$19,892.69
7	05457F	Denosumab	Injection 60 mg in 1 mL pre-filled syringe	349,787	\$94,846,259	\$98,434,759	\$281.41
8	08626B	Tiotropium	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate)	1,691,748	\$89,774,872	\$102,983,542	\$60.87
9	10657X	Sofosbuvir	Tablet 400 mg	4,277	\$85,580,105	\$85,654,451	\$20,026.76
10	08601Q	Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	2,856,500	\$81,947,602	\$105,908,501	\$37.08
11	08519J	Fluticasone + Salmeterol	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 microgram	1,449,601	\$81,763,205	\$102,169,779	\$70.48
12	09100Y	Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen	46,756	\$80,210,156	\$81,188,018	\$1,736.42
13	08600P	Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	3,456,516	\$72,881,811	\$89,653,341	\$25.94
14	10670N	Ledipasvir + Sofosbuvir	Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir	2,980	\$67,980,261	\$68,039,753	\$22,832.13
15	02268J	Rivaroxaban	Tablet 20 mg	885,445	\$66,928,051	\$79,363,854	\$89.63
16	08757X	Ezetimibe	Tablet 10 mg	1,195,215	\$66,290,405	\$82,103,658	\$68.69
17	09460X	Etanercept	Injection 50 mg in 1 mL single use auto-injector, 4	33,246	\$57,130,114	\$57,806,535	\$1,738.75
18	08814X	Paracetamol	Tablet 665 mg (modified release)	3,936,184	\$56,577,221	\$69,362,732	\$17.62
19	08435Y	Insulin Aspart	Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5	246,217	\$55,826,264	\$60,047,524	\$243.88
20	10174L	Enzalutamide	Capsule 40 mg	14,314	\$53,224,804	\$53,367,373	\$3,728.33
21	02335X	Pregabalin	Capsule 75 mg	1,443,639	\$52,679,321	\$69,890,363	\$48.41
22	09114Q	Imatinib	Tablet 400 mg (as mesilate)	13,410	\$52,139,133	\$52,397,898	\$3,907.37
23	08093Y	Goserelin	Subcutaneous implant (long acting) 10.8 mg (as acetate) in pre-filled injection syringe	46,050	\$49,580,251	\$50,050,681	\$1,086.88
24	09305R	Ustekinumab	Injection 45 mg in 0.5 mL	7,867	\$48,209,538	\$48,435,862	\$6,156.84
25	08609D	Insulin Aspart + Insulin Aspart Protamine	Injections (human analogue), cartridges, 30 units-70 units per mL, 3 mL, 5	203,122	\$47,813,534	\$50,013,088	\$246.22
26	09043Y	Rosuvastatin	Tablet 10 mg (as calcium)	2,409,085	\$46,400,176	\$58,634,082	\$24.34
27	02966D	Dimethyl Fumarate	Capsule (modified release) 240 mg	24,939	\$45,779,662	\$46,418,507	\$1,861.28
28	02355Y	Pregabalin	Capsule 150 mg	790,324	\$45,310,764	\$54,463,550	\$68.91
29	09191R	Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen	26,099	\$44,610,444	\$45,354,203	\$1,737.78
30	08625Y	Budesonide + Eformoterol	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eform	1,113,453	\$44,262,258	\$64,624,396	\$58.04
31	10642D	Daclatasvir	Tablet 60 mg	5,459	\$43,438,335	\$43,536,983	\$7,975.27
32	02698B	Abiraterone	Tablet containing abiraterone acetate 250 mg	10,558	\$38,277,581	\$38,374,659	\$3,634.65
33	09104E	Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen	21,778	\$37,217,818	\$37,828,492	\$1,737.00
34	08008L	Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	3,541,230	\$36,358,555	\$52,872,012	\$14.93
35	02735Y	Apixaban	Tablet 5 mg	422,636	\$35,639,078	\$40,816,668	\$96.58
36	10104T	Iron	Injection 500 mg (iron) in 10 mL	123,597	\$33,858,891	\$36,577,546	\$295.94
37	10659B	Daclatasvir	Tablet 60 mg	4,185	\$33,502,790	\$33,575,808	\$8,022.89
38	08750M	Budesonide + Eformoterol	Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eform	470,897	\$33,341,504	\$40,373,123	\$85.74
39	08215J	Atorvastatin	Tablet 40 mg (as calcium)	2,672,255	\$32,619,365	\$45,469,992	\$17.02
40	09102C	Adalimumab	Injection 40 mg in 0.8 mL pre-filled pen	18,766	\$32,089,821	\$32,592,634	\$1,736.79
41	09090K	Etanercept	Injections 50 mg in 1 mL single use pre-filled syringes	18,556	\$31,935,685	\$32,269,090	\$1,739.01
42	01221G	Abatacept	Injection 125 mg in 1 mL single dose pre-filled syringe	19,420	\$31,264,873	\$31,589,011	\$1,626.62
43	08288F	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	2,495,147	\$30,840,993	\$41,446,695	\$16.61
44	01382R	Ranibizumab	Solution for intravitreal injection 2.3 mg in 0.23 mL	20,930	\$30,316,532	\$30,548,458	\$1,459.55
45	08432T	Fluticasone + Salmeterol	Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 microgram	512,883	\$29,427,095	\$36,453,822	\$71.08
46	08741C	Adalimumab	Injection 40 mg in 0.8 mL pre-filled syringe	16,604	\$28,524,484	\$28,847,488	\$1,737.38
47	10374B	Ranibizumab	Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe	16,287	\$28,236,864	\$28,525,839	\$1,751.45
48	10003L	Dabrafenib	Capsule 75 mg (as mesilate)	3,140	\$28,086,919	\$28,147,610	\$8,964.21
49	10668L	Ledipasvir + Sofosbuvir	Tablet containing 90 mg ledipasvir with 400 mg sofosbuvir	1,206	\$27,086,890	\$27,111,849	\$22,480.80
50	02363J	Pregabalin	Capsule 300 mg	307,590	\$26,782,731	\$30,129,775	\$97.95

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

**Table 11(b): PBS Items Sorted by Highest Script Volume, 2015-16.**  
Section 85 only; incl. Drs Bag.

Rank	Item Code	Drug	Form	Script Volume	Government Cost	Total Cost*	Ave. Price**
1	08814X	Paracetamol	Tablet 665 mg (modified release)	3,936,184	\$56,577,221	\$69,362,732	\$17.62
2	08008L	Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	3,541,230	\$36,358,555	\$52,872,012	\$14.93
3	08600P	Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	3,456,516	\$72,881,811	\$89,653,341	\$25.94
4	08601Q	Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	2,856,500	\$81,947,602	\$105,908,501	\$37.08
5	08215J	Atorvastatin	Tablet 40 mg (as calcium)	2,672,255	\$32,619,365	\$45,469,992	\$17.02
6	01081X	Atenolol	Tablet 50 mg	2,579,885	\$18,190,610	\$30,505,586	\$11.82
7	08288F	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	2,495,147	\$30,840,993	\$41,446,695	\$16.61
8	09043Y	Rosuvastatin	Tablet 10 mg (as calcium)	2,409,085	\$46,400,176	\$58,634,082	\$24.34
9	03119E	Cephalexin	Capsule 500 mg (anhydrous)	2,317,439	\$16,166,248	\$27,773,890	\$11.98
10	08214H	Atorvastatin	Tablet 20 mg (as calcium)	2,274,496	\$22,941,081	\$34,208,286	\$15.04
11	08254K	Amoxicillin + Clavulanic Acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid	1,760,232	\$14,401,037	\$23,153,389	\$13.15
12	08508T	Rabeprazole	Tablet containing rabeprazole sodium 20 mg (enteric coated)	1,701,130	\$22,302,219	\$30,463,173	\$17.91
13	08626B	Tiotropium	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate)	1,691,748	\$89,774,872	\$102,983,542	\$60.87
14	03162K	Diazepam	Tablet 5 mg	1,568,417	\$9,920,406	\$17,460,790	\$11.13
15	08358X	Clopidogrel	Tablet 75 mg (as hydrogen sulfate)	1,531,633	\$20,387,026	\$27,133,225	\$17.72
16	02622B	Oxycodone	Tablet containing oxycodone hydrochloride 5 mg	1,488,017	\$20,647,839	\$27,809,712	\$18.69
17	02089Y	Temazepam	Tablet 10 mg	1,485,290	\$9,624,496	\$16,275,962	\$10.96
18	08519J	Fluticasone + Salmeterol	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 microgram	1,449,601	\$81,763,205	\$102,169,779	\$70.48
19	02335X	Pregabalin	Capsule 75 mg	1,443,639	\$52,679,321	\$69,890,363	\$48.41
20	01889K	Amoxicillin	Capsule 500 mg (as trihydrate)	1,413,789	\$9,251,222	\$16,591,199	\$11.74
21	02751T	Amlodipine	Tablet 5 mg (as besylate)	1,411,709	\$9,445,736	\$16,275,739	\$11.53
22	01215Y	Paracetamol + Codeine	Tablet containing codeine phosphate 30 mg with paracetamol 500 mg	1,378,211	\$8,674,967	\$15,287,738	\$11.09
23	01324Q	Metoprolol Tartrate	Tablet containing metoprolol tartrate 50 mg	1,364,147	\$10,728,641	\$16,879,558	\$12.37
24	08248D	Irbesartan	Tablet 300 mg	1,245,725	\$15,955,625	\$22,011,304	\$17.67
25	09042X	Rosuvastatin	Tablet 5 mg (as calcium)	1,239,607	\$18,175,903	\$24,511,612	\$19.77
26	08757X	Ezetimibe	Tablet 10 mg	1,195,215	\$66,290,405	\$82,103,658	\$68.69
27	08612G	Macrogol-3350 + Sodium Chloride + Bicarbonate + Potassium Chloride	Sachets containing powder for oral solution 13.125 g with electrolytes, 30	1,158,781	\$19,706,663	\$24,459,794	\$21.11
28	08625Y	Budesonide + Eformoterol	Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eform	1,113,453	\$44,262,258	\$64,624,396	\$58.04
29	09302N	Gliclazide	Tablet 60 mg (modified release)	1,109,987	\$14,717,251	\$19,372,690	\$17.45
30	08213G	Atorvastatin	Tablet 10 mg (as calcium)	1,106,409	\$9,333,227	\$14,892,686	\$13.46
31	08355R	Telmisartan	Tablet 40 mg	1,104,955	\$10,501,423	\$16,217,862	\$14.68
32	08243W	Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	1,095,294	\$22,231,333	\$27,269,372	\$24.90
33	08405J	Irbesartan + Hydrochlorothiazide	Tablet 300 mg-12.5 mg	1,092,717	\$15,522,257	\$20,972,715	\$19.19
34	02412Y	Frusamide	Tablet 40 mg	1,088,897	\$8,233,669	\$12,455,444	\$11.44
35	08247C	Irbesartan	Tablet 150 mg	1,079,095	\$9,652,589	\$15,073,439	\$13.97
36	08173E	Simvastatin	Tablet 40 mg	1,053,023	\$9,341,449	\$14,341,377	\$13.62
37	03439B	Metformin	Tablet (extended release) containing metformin hydrochloride 1 g	988,948	\$10,557,518	\$14,891,257	\$15.06
38	08521L	Atorvastatin	Tablet 80 mg (as calcium)	985,027	\$15,029,030	\$19,620,608	\$19.92
39	09110L	Omeprazole	Tablet 20 mg (as magnesium)	948,435	\$12,820,850	\$17,329,012	\$18.27
40	02237R	Sertraline	Tablet 100 mg (as hydrochloride)	943,609	\$8,117,563	\$12,833,900	\$13.60
41	08356T	Telmisartan	Tablet 80 mg	936,948	\$17,007,878	\$21,744,720	\$23.21
42	08302Y	Venlafaxine	Capsule (modified release) 150 mg (as hydrochloride)	900,841	\$15,093,633	\$20,055,594	\$22.26
43	09023X	Fenofibrate	Tablet 145 mg	899,547	\$23,211,047	\$36,815,148	\$40.93
44	09044B	Rosuvastatin	Tablet 20 mg (as calcium)	887,379	\$22,504,641	\$26,969,198	\$30.39
45	02268J	Rivaroxaban	Tablet 20 mg	885,445	\$66,928,051	\$79,363,854	\$89.63
46	02752W	Amlodipine	Tablet 10 mg (as besylate)	875,393	\$6,724,690	\$10,872,884	\$12.42
47	08534E	Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	872,593	\$7,255,273	\$11,391,877	\$13.06
48	02236Q	Sertraline	Tablet 50 mg (as hydrochloride)	869,086	\$6,746,554	\$11,068,797	\$12.74
49	09435N	Metformin	Tablet (extended release) containing metformin hydrochloride 500 mg	855,198	\$9,092,870	\$12,830,773	\$15.00
50	03051N	Perindopril	Tablet containing perindopril erbumine 4 mg	845,303	\$8,315,965	\$12,536,589	\$14.83

\* Total Cost includes cost to the patient and cost to the government.

\*\* Average Price is Total Cost divided by Script Volume.

**Table 12: ATC Level 2 Drug Groups Sorted by Highest Script Volume, 2015-16.**

Includes subsidised and under co-payment scripts.

Section 85 only; incl. Drs Bag.

Rank	ATC Group Level 2	Subsidised (Over Co- payment) Scripts	Under Co- payment Scripts	Total Scripts
1	Agents Acting On The Renin-Angiotensin System	23,515,943	12,303,428	35,819,371
2	Lipid Modifying Agents	21,918,722	7,220,549	29,139,271
3	Antibacterials For Systemic Use	13,175,415	15,142,657	28,318,072
4	Psychoanaleptics	15,758,704	10,086,372	25,845,076
5	Analgesics	20,025,519	4,792,884	24,818,403
6	Drugs For Acid Related Disorders	16,630,973	6,077,761	22,708,734
7	Drugs For Obstructive Airway Diseases	11,665,730	1,305,830	12,971,560
8	Drugs Used In Diabetes	9,607,366	2,172,511	11,779,877
9	Psycholeptics	7,904,740	1,763,324	9,668,064
10	Antithrombotic Agents	8,348,653	1,000,388	9,349,041
11	Calcium Channel Blockers	6,526,167	2,190,075	8,716,242
12	Ophthalmologicals	7,265,279	1,392,019	8,657,298
13	Beta Blocking Agents	6,218,726	1,991,720	8,210,446
14	Antiinflammatory And Antirheumatic Products	4,046,907	3,021,560	7,068,467
15	Sex Hormones And Modulators Of The Genital System	2,148,093	3,219,775	5,367,868
16	Corticosteroids For Systemic Use	2,293,051	1,784,901	4,077,952
17	Corticosteroids, Dermatological Preparations	2,275,598	1,377,628	3,653,226
18	Cardiac Therapy	3,049,304	435,607	3,484,911
19	Diuretics	2,350,085	467,701	2,817,786
20	Antiepileptics	2,227,207	470,556	2,697,763
21	Drugs For Treatment Of Bone Diseases	2,433,569	55,083	2,488,652
22	Antihypertensives	1,507,042	428,742	1,935,784
23	Thyroid Therapy	1,066,561	809,990	1,876,551
24	Antigout Preparations	1,155,022	679,677	1,834,699
25	Drugs For Constipation	1,516,784	78,614	1,595,398
26	Drugs For Functional Gastrointestinal Disorders	921,787	477,305	1,399,092
27	Antiemetics And Antinauseants	938,083	412,334	1,350,417
28	Urologicals	1,024,326	194,537	1,218,863
29	Anti-Parkinson Drugs	1,111,378	86,011	1,197,389
30	Otologicals	628,150	510,523	1,138,673
31	Antidiarrheals, Intestinal Antiinflammatory/Anti-infective Agents	973,203	82,785	1,055,988
32	Immunosuppressants	1,013,225	31,886	1,045,111
33	Antianemic Preparations	836,975	126,908	963,883
34	Endocrine Therapy	783,048	84,816	867,864
35	Antivirals For Systemic Use	741,542	78,933	820,475
36	Other Nervous System Drugs	633,797	1,888	635,685
37	Antineoplastic Agents	487,161	63,847	551,008
38	Diagnostic Agents	396,302	190	396,492
39	Anti-Acne Preparations	229,490	129,836	359,326
40	Mineral Supplements	283,052	51,787	334,839
41	Antipsoriatics	261,682	1,112	262,794
42	Cough And Cold Preparations	166,772	75,822	242,594
43	Stomatological Preparations	173,625	63,066	236,691
44	Muscle Relaxants	166,147	41,441	207,588
45	Not otherwise specified	158,281	46,971	205,252
46	Other Gynecologicals	167,023	6,317	173,340
47	Antifungals For Dermatological Use	104,622	44,857	149,479
48	Vitamins	118,912	27,667	146,579
49	Digestives, Incl. Enzymes	132,260	157	132,417
50	Pituitary And Hypothalamic Hormones And Analogues	88,362	37	88,399

**Table 13: PBS Drugs (Generic Name) Sorted by Highest Script Volume, 2015-16.**

Includes subsidised and under co-payment scripts.

Section 85 only; incl. Drs Bag.

Rank	Drug	Subsidised (Over Co- payment) Scripts	Under Co- payment Scripts	Total Scripts
1	Atorvastatin	7,490,700	2,983,610	10,474,310
2	Rosuvastatin	6,465,792	3,290,095	9,755,887
3	Esomeprazole	6,747,706	2,200,471	8,948,177
4	Pantoprazole	4,586,606	1,824,809	6,411,415
5	Perindopril	3,956,980	2,186,773	6,143,753
6	Amoxicillin	2,366,406	3,460,548	5,826,954
7	Cephalexin	2,796,175	2,772,673	5,568,848
8	Paracetamol	4,946,779	240,477	5,187,256
9	Metformin	3,553,833	1,605,535	5,159,368
10	Amoxicillin + Clavulanic Acid	2,245,060	2,802,617	5,047,677
11	Irbesartan	2,854,173	1,309,967	4,164,140
12	Paracetamol + Codeine	2,277,953	1,448,965	3,726,918
13	Sertraline	1,887,189	1,826,155	3,713,344
14	Salbutamol	2,953,779	741,808	3,695,587
15	Escitalopram	1,701,964	1,941,198	3,643,162
16	Oxycodone	2,469,309	1,073,798	3,543,107
17	Atenolol	2,580,430	945,689	3,526,119
18	Telmisartan	2,041,927	1,279,582	3,321,509
19	Pregabalin	3,150,492	139,628	3,290,120
20	Ramipril	2,219,371	1,058,360	3,277,731
21	Amlodipine	2,287,286	911,950	3,199,236
22	Simvastatin	2,485,415	633,178	3,118,593
23	Candesartan	2,046,936	1,062,981	3,109,917
24	Fluticasone + Salmeterol	3,006,437	44	3,006,481
25	Venlafaxine	1,721,646	1,187,056	2,908,702
26	Rabeprazole	1,928,722	904,521	2,833,243
27	Irbesartan + Hydrochlorothiazide	1,936,369	879,298	2,815,667
28	Tramadol	1,955,057	778,281	2,733,338
29	Diazepam	1,768,171	694,254	2,462,425
30	Omeprazole	1,778,603	682,817	2,461,420
31	Meloxicam	1,498,384	956,581	2,454,965
32	Warfarin	1,968,998	481,256	2,450,254
33	Clopidogrel	1,900,880	360,722	2,261,602
34	Lercanidipine	1,678,257	525,664	2,203,921
35	Metoprolol Tartrate	1,672,150	492,948	2,165,098
36	Levonorgestrel + Ethinylloestradiol	488,678	1,676,214	2,164,892
37	Mirtazapine	1,606,123	532,634	2,138,757
38	Prednisolone	1,246,019	891,962	2,137,981
39	Amitriptyline	1,470,197	653,433	2,123,630
40	Desvenlafaxine	1,464,961	604,902	2,069,863
41	Temazepam	1,508,526	555,592	2,064,118
42	Doxycycline	980,296	1,079,748	2,060,044
43	Perindopril + Amlodipine	1,402,630	550,343	1,952,973
44	Gliclazide	1,405,115	442,963	1,848,078
45	Budesonide + Eformoterol	1,829,094	1,517	1,830,611
46	Oxycodone + Naloxone	1,538,559	251,000	1,789,559
47	Tiotropium	1,786,709	56	1,786,765
48	Thyroxine	970,016	760,464	1,730,480
49	Citalopram	985,507	742,888	1,728,395
50	Fluoxetine	868,667	834,215	1,702,882

**Table 14: PBS Items Sorted by Highest Script Volume, 2015-16.**

Includes subsidised and under co-payment scripts.

Section 85 only; incl. Drs Bag.

Rank	Item Code	Drug	Form	Subsidised (Over Co-payment) Scripts	Under Co-payment Scripts	Total Scripts
1	08600P	Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	3,456,516	1,608,020	5,064,536
2	08008L	Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	3,541,230	1,305,075	4,846,305
3	03119E	Cephalexin	Capsule 500 mg (anhydrous)	2,317,439	2,200,200	4,517,639
4	08814X	Paracetamol	Tablet 665 mg (modified release)	3,936,184	134,374	4,070,558
5	08254K	Amoxicillin + Clavulanic Acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid	1,760,232	2,096,590	3,856,822
6	09043Y	Rosuvastatin	Tablet 10 mg (as calcium)	2,409,085	1,335,417	3,744,502
7	08215J	Atorvastatin	Tablet 40 mg (as calcium)	2,672,255	1,022,026	3,694,281
8	01081X	Atenolol	Tablet 50 mg	2,579,885	945,171	3,525,056
9	08601Q	Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	2,856,500	414,214	3,270,714
10	01889K	Amoxicillin	Capsule 500 mg (as trihydrate)	1,413,789	1,833,413	3,247,202
11	08214H	Atorvastatin	Tablet 20 mg (as calcium)	2,274,496	937,691	3,212,187
12	08288F	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)	2,495,147	677,692	3,172,839
13	01215Y	Paracetamol + Codeine	Tablet containing codeine phosphate 30 mg with paracetamol 500 mg	1,378,211	1,181,567	2,559,778
14	08508T	Rabeprazole	Tablet containing rabeprazole sodium 20 mg (enteric coated)	1,701,130	787,630	2,488,760
15	02622B	Oxycodone	Tablet containing oxycodone hydrochloride 5 mg	1,488,017	900,628	2,388,645
16	03162K	Diazepam	Tablet 5 mg	1,568,417	580,707	2,149,124
17	02089Y	Temazepam	Tablet 10 mg	1,485,290	552,664	2,037,954
18	02751T	Amlodipine	Tablet 5 mg (as besylate)	1,411,709	533,784	1,945,493
19	09042X	Rosuvastatin	Tablet 5 mg (as calcium)	1,239,607	646,200	1,885,807
20	08355R	Telmisartan	Tablet 40 mg	1,104,955	745,806	1,850,761
21	02237R	Sertraline	Tablet 100 mg (as hydrochloride)	943,609	885,958	1,829,567
22	08358X	Clopidogrel	Tablet 75 mg (as hydrogen sulfate)	1,531,633	293,641	1,825,274
23	08700X	Escitalopram	Tablet 10 mg (as oxalate)	825,741	982,227	1,807,968
24	08248D	Irbesartan	Tablet 300 mg	1,245,725	535,288	1,781,013
25	01324Q	Metoprolol Tartrate	Tablet containing metoprolol tartrate 50 mg	1,364,147	407,375	1,771,522
26	02236Q	Sertraline	Tablet 50 mg (as hydrochloride)	869,086	873,047	1,742,133
27	01394J	Levonorgestrel + Ethinylloestradiol	Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets	391,572	1,349,321	1,740,893
28	08701Y	Escitalopram	Tablet 20 mg (as oxalate)	831,653	904,413	1,736,066
29	08626B	Tiotropium	Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate)	1,691,748	56	1,691,804
30	08247C	Irbesartan	Tablet 150 mg	1,079,095	555,188	1,634,283
31	08405J	Irbesartan + Hydrochlorothiazide	Tablet 300 mg-12.5 mg	1,092,717	486,896	1,579,613
32	08213G	Atorvastatin	Tablet 10 mg (as calcium)	1,106,409	446,155	1,552,564
33	03439B	Metformin	Tablet (extended release) containing metformin hydrochloride 1 g	988,948	549,803	1,538,751
34	03051N	Perindopril	Tablet containing perindopril erbumine 4 mg	845,303	641,890	1,487,193
35	09302N	Gliclazide	Tablet 60 mg (modified release)	1,109,987	373,518	1,483,505
36	08356T	Telmisartan	Tablet 80 mg	936,948	533,773	1,470,721
37	08519J	Fluticasone + Salmeterol	Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 microgram	1,449,601	2	1,449,603
38	02335X	Pregabalin	Capsule 75 mg	1,443,639	3,101	1,446,740
39	08302Y	Venlafaxine	Capsule (modified release) 150 mg (as hydrochloride)	900,841	540,238	1,441,079
40	09044B	Rosuvastatin	Tablet 20 mg (as calcium)	887,379	532,081	1,419,460
41	08521L	Atorvastatin	Tablet 80 mg (as calcium)	985,027	391,621	1,376,648
42	08220P	Citalopram	Tablet 20 mg (as hydrobromide)	759,333	590,150	1,349,483
43	09110L	Omeprazole	Tablet 20 mg (as magnesium)	948,435	385,803	1,334,238
44	08173E	Simvastatin	Tablet 40 mg	1,053,023	268,605	1,321,628
45	08243W	Latanoprost	Eye drops 50 micrograms per mL, 2.5 mL	1,095,294	219,713	1,315,007
46	08440F	Celecoxib	Capsule 200 mg	837,201	471,961	1,309,162
47	01434L	Fluoxetine	Capsule 20 mg (as hydrochloride)	663,960	641,687	1,305,647
48	08301X	Venlafaxine	Capsule (modified release) 75 mg (as hydrochloride)	715,071	552,144	1,267,215
49	02752W	Amlodipine	Tablet 10 mg (as besylate)	875,393	378,151	1,253,544
50	09435N	Metformin	Tablet (extended release) containing metformin hydrochloride 500 mg	855,198	387,133	1,242,331

**Table 15: PBS Processing by Formulary, 2015-16.**

Section 85 only; excl. Drs Bag.

<b>Formulary<sup>1,3</sup></b>	<b>Script Volume</b>	<b>Percentage of Total</b>	<b>Government Cost</b>	<b>Percentage of Total</b>
<b>F1</b>	30,639,847	14.8%	\$4,254,605,804	53.5%
<b>F2</b>	162,882,114	78.5%	\$2,659,803,481	33.5%
<b>Combination Drugs</b>	13,539,777	6.5%	\$1,014,799,301	12.8%
<b>Other<sup>2</sup></b>	539,392	0.3%	\$19,809,668	0.2%
<b>Total</b>	<b>207,601,130</b>	<b>100.0%</b>	<b>\$7,949,018,254</b>	<b>100.0%</b>

**Notes:**

1. Scripts are matched to their formulary at the date of supply.

2. Not classified to a formulary. e.g. Extemporaneously Prepared, unknown.

3. The National Health Act 1953 provides that listed drugs be assigned to formularies identified as F1 or F2.

Generally F1 is intended for single brand drugs and F2 for drugs that have multiple brands, or are in a therapeutic group with other drugs with multiple brands.

Drugs on F2 are subject to the provisions of the Act relating to statutory price reductions, price disclosure and guarantee of supply.

Allocation to F1 or F2 is determined by legislative instrument.

Single brand combination drugs are not included in either the F1 or F2 formulary.

Expenditure and Prescriptions 2015-16.

**Table16(a): Top 20 Responsible Persons by Total Cost, 2015-16.**

Section 85 only; incl. Drs Bag

Rank	Responsible Person	Script Volume	Government Cost	Total Cost	Derived Ex-manufacturer Sales
1	Novartis Pharmaceuticals Australia Pty Limited	3,505,261	\$797,915,017	<b>\$830,219,127</b>	\$744,453,958
2	Pfizer Australia Pty Ltd	13,568,550	\$606,521,783	<b>\$725,753,195</b>	\$543,344,640
3	Astrazeneca Pty Ltd	13,074,617	\$458,167,408	<b>\$574,624,161</b>	\$406,659,898
4	Gilead Sciences Pty Limited	26,413	\$569,801,042	<b>\$570,318,871</b>	\$553,330,183
5	Alphapharm Pty Ltd	29,952,583	\$398,565,938	<b>\$553,088,554</b>	\$217,891,880
6	Apotex Pty Ltd	29,000,832	\$388,636,963	<b>\$538,376,559</b>	\$217,122,190
7	Merck Sharp & Dohme (Australia) Pty Ltd	8,754,705	\$359,218,385	<b>\$448,923,007</b>	\$328,707,730
8	Bayer Australia Ltd	2,722,510	\$389,843,610	<b>\$420,147,469</b>	\$361,895,143
9	Sanofi-Aventis Australia Pty Ltd	10,263,718	\$353,904,865	<b>\$415,628,733</b>	\$284,730,866
10	Abbvie Pty Ltd	221,678	\$385,727,920	<b>\$390,893,733</b>	\$363,532,055
11	Janssen-Cilag Pty Ltd	2,488,876	\$328,786,435	<b>\$348,723,675</b>	\$298,359,919
12	Aspen Pharmacare Pty Ltd	16,854,712	\$239,182,719	<b>\$325,370,292</b>	\$128,171,487
13	Glaxosmithkline Australia Pty Ltd	7,758,375	\$246,765,085	<b>\$316,225,343</b>	\$219,500,279
14	Boehringer Ingelheim Pty Ltd	6,011,339	\$209,008,280	<b>\$249,730,170</b>	\$174,232,661
15	Bristol-Myers Squibb Australia Pty Ltd	1,093,060	\$232,569,060	<b>\$243,385,948</b>	\$219,141,868
16	Sandoz Pty Ltd	12,496,520	\$173,807,370	<b>\$242,522,450</b>	\$102,813,010
17	Mundipharma Pty Limited	4,188,372	\$180,288,288	<b>\$208,330,591</b>	\$137,005,643
18	Novo Nordisk Pharmaceuticals Pty Limited	1,026,817	\$152,387,306	<b>\$163,426,634</b>	\$140,746,103
19	Amgen Australia Pty Limited	407,987	\$123,543,466	<b>\$127,985,832</b>	\$113,533,179
20	BGP Products Pty Ltd	3,528,620	\$80,930,265	<b>\$108,616,671</b>	\$66,806,203
	Others (total)	41,044,444	\$1,289,334,199.75	<b>\$1,556,819,527.35</b>	\$1,035,156,392.37
	<b>Total</b>	<b>207,989,989</b>	<b>\$7,964,905,404</b>	<b>\$9,359,110,541</b>	<b>\$6,657,135,284</b>

Notes:

"Others" contains some scripts where the manufacturer is unknown.

Total Cost includes cost to the patient and cost to the government.

Expenditure and Prescriptions 2015-16.

**Table16(b): Top 20 Responsible Persons by Market Share (Scripts), 2015-16.**

Section 85 only; incl. Drs Bag

Rank	Responsible Person	Script Volume	Government Cost	Total Cost	Percentage of Total Scripts	Derived Ex-manufacturer Sales
1	Alphapharm Pty Ltd	29,952,583	\$398,565,938	\$553,088,554	14.40%	\$217,891,880
2	Apotex Pty Ltd	29,000,832	\$388,636,963	\$538,376,559	13.94%	\$217,122,190
3	Aspen Pharmacare Pty Ltd	16,854,712	\$239,182,719	\$325,370,292	8.10%	\$128,171,487
4	Pfizer Australia Pty Ltd	13,568,550	\$606,521,783	\$725,753,195	6.52%	\$543,344,640
5	Astrazeneca Pty Ltd	13,074,617	\$458,167,408	\$574,624,161	6.29%	\$406,659,898
6	Sandoz Pty Ltd	12,496,520	\$173,807,370	\$242,522,450	6.01%	\$102,813,010
7	Sanofi-Aventis Australia Pty Ltd	10,263,718	\$353,904,865	\$415,628,733	4.93%	\$284,730,866
8	Merck Sharp & Dohme (Australia) Pty Ltd	8,754,705	\$359,218,385	\$448,923,007	4.21%	\$328,707,730
9	Glaxosmithkline Australia Pty Ltd	7,758,375	\$246,765,085	\$316,225,343	3.73%	\$219,500,279
10	Boehringer Ingelheim Pty Ltd	6,011,339	\$209,008,280	\$249,730,170	2.89%	\$174,232,661
11	Servier Laboratories (Aust)pty Ltd	4,387,136	\$70,059,474	\$98,715,345	2.11%	\$49,891,041
12	Fawns & Mcallan Proprietary Limited	4,238,417	\$55,833,925	\$75,360,998	2.04%	\$28,605,470
13	Mundipharma Pty Limited	4,188,372	\$180,288,288	\$208,330,591	2.01%	\$137,005,643
14	Bgp Products Pty Ltd	3,528,620	\$80,930,265	\$108,616,671	1.70%	\$66,806,203
15	Novartis Pharmaceuticals Australia Pty Limited	3,505,261	\$797,915,017	\$830,219,127	1.69%	\$744,453,958
16	Arrow Pharma Pty Ltd	2,998,836	\$32,452,694	\$51,382,078	1.44%	\$18,339,275
17	Bayer Australia Ltd	2,722,510	\$389,843,610	\$420,147,469	1.31%	\$361,895,143
18	Amneal Pharmaceuticals Pty Ltd	2,523,404	\$34,985,006	\$48,677,454	1.21%	\$20,097,788
19	Janssen-Cilag Pty Ltd	2,488,876	\$328,786,435	\$348,723,675	1.20%	\$298,359,919
20	Alcon Laboratories (Australia) Pty Ltd	2,312,750	\$41,257,051	\$53,418,100	1.11%	\$27,587,092
	<b>Top 20 (total)</b>	<b>180,630,133</b>	<b>\$5,446,130,560</b>	<b>\$6,633,833,970</b>	<b>86.85%</b>	<b>\$4,376,216,171</b>
	<b>Others (total)</b>	<b>27,359,856</b>	<b>\$2,518,774,844</b>	<b>\$2,725,276,571</b>	<b>13.15%</b>	<b>\$2,280,919,112</b>
	<b>Total</b>	<b>207,989,989</b>	<b>\$7,964,905,404</b>	<b>\$9,359,110,541</b>	<b>100.00%</b>	<b>\$6,657,135,284</b>

Notes:

"Others" contains some scripts where the manufacturer is unknown.

Total Cost includes cost to the patient and cost to the government.

**Table 17(a): Safety Net Card Issues - Persons Covered, 2010 to 2015**

Monthly Comparison 2010, 2011, 2012, 2013, 2014 and 2015

No of people (cumulative each Month)

		JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
<b>General Safety Net</b>	<b>2010</b>	0	23	281	1,784	8,399	24,062	51,538	89,020	134,981	183,904	237,868	312,736
	<b>2011</b>	2	28	232	1,370	7,645	22,218	47,299	83,989	127,952	174,862	226,258	298,519
	<b>2012</b>	3	30	223	1,257	6,561	18,432	40,424	72,995	108,154	152,704	199,512	264,807
	<b>2013</b>	11	45	208	1,107	5,823	15,600	35,749	63,034	95,012	135,150	175,282	236,942
	<b>2014</b>	2	16	139	846	4,552	12,711	28,785	50,241	78,227	112,025	144,334	197,660
	<b>2015</b>	2	23	117	764	3,298	10,138	23,139	42,195	67,719	96,582	129,145	178,574
<b>Concessional Safety Net</b>	<b>2010</b>	14	271	3,647	22,595	93,650	225,213	406,808	606,628	807,300	994,906	1,177,148	1,400,218
	<b>2011</b>	13	307	3,463	19,445	95,885	231,227	410,453	621,889	825,698	1,018,881	1,203,783	1,430,779
	<b>2012</b>	21	342	3,501	22,207	103,733	241,158	432,266	648,030	841,310	1,050,790	1,238,208	1,457,538
	<b>2013</b>	19	332	3,072	23,438	109,989	242,719	447,258	660,734	862,593	1,074,825	1,254,453	1,490,953
	<b>2014</b>	23	314	3,861	23,232	109,657	255,357	466,457	672,010	890,547	1,104,875	1,280,230	1,526,245
	<b>2015</b>	10	320	4,139	29,678	113,595	269,548	474,734	690,322	911,899	1,113,504	1,306,458	1,550,366
<b>#Supplementary</b>	<b>2010</b>	0	20	272	2,239	9,399	22,408	39,240	57,376	76,072	92,323	106,952	123,252
	<b>2011</b>	0	18	313	2,274	11,144	26,289	46,110	68,475	89,754	109,243	126,896	145,031
	<b>2012</b>	0	42	438	2,962	13,825	31,405	55,151	81,655	103,734	127,464	147,349	168,577
	<b>2013</b>	6	62	466	3,647	16,094	35,223	64,878	94,319	121,281	147,220	168,753	193,444
	<b>2014</b>	2	42	558	3,630	18,829	41,656	74,411	105,377	137,360	167,295	189,984	217,718
	<b>2015</b>	2	57	722	5,598	21,874	51,080	87,364	126,559	162,750	192,912	219,815	249,849
<b>TOTAL</b>	<b>2010</b>	14	314	4,200	26,618	111,448	271,683	497,586	753,024	1,018,353	1,271,133	1,521,968	1,836,206
	<b>2011</b>	15	353	4,008	23,089	114,674	279,734	503,862	774,353	1,043,404	1,302,986	1,556,937	1,874,329
	<b>2012</b>	24	414	4,162	26,426	124,119	290,995	527,841	802,680	1,053,198	1,330,958	1,585,069	1,890,922
	<b>2013</b>	36	439	3,746	28,192	131,906	293,542	547,885	818,087	1,078,886	1,357,195	1,598,488	1,921,339
	<b>2014</b>	27	372	4,558	27,708	133,038	309,724	569,653	827,628	1,106,134	1,384,195	1,614,548	1,941,623
	<b>2015</b>	14	400	4,978	36,040	138,767	330,766	585,237	859,076	1,142,368	1,402,998	1,655,418	1,978,789

# Safety Net Cards issued due to remote family members or loss of the original card.

Source: Department of Human Services (RSN003)

**Table 17(b): Safety Net Card Issues - Number of Cards, 2010 to 2015**

Monthly Comparison 2010, 2011, 2012, 2013, 2014 and 2015

No of cards (cumulative per month)

		JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
<b>General Safety Net</b>	<b>2010</b>	0	13	144	887	4,154	11,876	25,377	43,882	66,649	91,044	118,099	156,605
	<b>2011</b>	1	12	116	680	3,777	10,916	23,321	41,487	63,211	86,645	112,576	149,941
	<b>2012</b>	2	16	105	618	3,234	9,013	19,910	36,015	53,420	75,765	99,404	133,130
	<b>2013</b>	6	27	102	528	2,879	7,700	17,655	31,201	47,045	67,257	87,675	119,463
	<b>2014</b>	1	9	68	404	2,201	6,224	14,191	24,842	38,870	55,981	72,522	100,316
	<b>2015</b>	1	9	53	370	1,590	4,958	11,415	20,876	33,657	48,423	65,281	91,460
<b>Concessional Safety Net</b>	<b>2010</b>	8	130	1,822	11,585	49,597	122,207	226,023	343,811	465,869	583,431	700,455	848,872
	<b>2011</b>	7	140	1,672	9,933	50,992	125,877	228,019	353,145	477,637	599,093	718,589	870,086
	<b>2012</b>	12	161	1,713	11,430	55,451	131,837	241,713	370,015	488,708	621,585	743,616	890,881
	<b>2013</b>	11	165	1,519	12,163	59,199	133,042	251,167	378,590	503,012	638,285	755,847	915,189
	<b>2014</b>	12	147	1,878	12,061	58,903	140,470	262,697	385,582	520,369	657,399	772,631	939,146
	<b>2015</b>	7	164	2,024	15,316	60,544	147,613	266,020	394,532	531,444	660,676	787,347	954,451
<b>#Supplementary</b>	<b>2010</b>	0	8	129	1,052	4,500	10,786	18,905	27,563	36,418	44,096	50,990	58,627
	<b>2011</b>	0	9	141	1,080	5,363	12,674	22,248	32,951	43,113	52,412	60,718	69,181
	<b>2012</b>	0	21	199	1,396	6,663	15,140	26,609	39,344	49,899	61,244	70,629	80,601
	<b>2013</b>	3	28	207	1,728	7,717	16,963	31,287	45,456	58,414	70,807	81,019	92,643
	<b>2014</b>	1	18	253	1,728	9,070	20,092	35,924	50,852	66,130	80,421	91,168	104,250
	<b>2015</b>	1	25	330	2,645	10,447	24,579	42,164	61,030	78,449	92,859	105,658	119,969
<b>TOTAL</b>	<b>2010</b>	8	151	2,095	13,524	58,251	144,869	270,305	415,256	568,936	718,571	869,544	1,064,104
	<b>2011</b>	8	161	1,929	11,693	60,132	149,467	273,588	427,583	583,961	738,150	891,883	1,089,208
	<b>2012</b>	14	198	2,017	13,444	65,348	155,990	288,232	445,374	592,027	758,594	913,649	1,104,612
	<b>2013</b>	20	220	1,828	14,419	69,795	157,705	300,109	455,247	608,471	776,349	924,541	1,127,295
	<b>2014</b>	14	174	2,199	14,193	70,174	166,786	312,812	461,276	625,369	793,801	936,321	1,143,712
	<b>2015</b>	9	198	2,407	18,331	72,581	177,150	319,599	476,438	643,550	801,958	958,286	1,165,880

# Safety Net Cards issued due to remote family members or loss of the original card.

Source: Department of Human Services (RSN002)

**Table 18: Number of Pharmacies and Friendly Societies, 30 June 2012 to 2016.**

Status as at 30 June, 2012 - 2016.

Approved Pharmacies and Friendly Societies						Approved Doctors
	2012	2013	2014	2015	2016	2016
<b>NSW</b>	1,772	1,802	1,818	1,827	1,847	8
<b>Vic.</b>	1,243	1,261	1,282	1,296	1,313	1
<b>Qld</b>	1,066	1,076	1,088	1,099	1,117	4
<b>SA</b>	426	436	438	438	447	1
<b>WA</b>	550	564	574	585	592	4
<b>Tas.</b>	144	148	148	149	150	3
<b>NT</b>	32	33	33	34	35	0
<b>ACT</b>	69	73	73	75	76	0
<b>Australia</b>	<b>5,302</b>	<b>5,393</b>	<b>5,454</b>	<b>5,503</b>	<b>5,577</b>	<b>21</b>

Source: Department of Human Services (RPC015)

**Table 19: PBS Special Patient Contributions, 2013-14 to 2015-16.**

Section 85 only.

	2013-14	2014-15	2015-16
Number of brands listed on the PBS <sup>(a)</sup>	4,486	5,002	4,993
Number of brands with a premium <sup>(a)</sup>	274	282	314
% of brands with a premium	6.1%	5.6%	6.3%
Average brand premium	\$2.71	\$2.80	\$2.95
Weighted average brand premium <sup>(b)</sup>	\$2.58	\$2.58	\$2.48
Brand premium range	\$0.43 to \$11.41	\$0.37 to \$14.37	\$0.19 to \$14.20
Prescriptions (millions) dispensed with a brand premium <sup>(c)</sup>	13.1 m	16.3 m	18.0 m
Prescriptions (millions) dispensed at the benchmark level <sup>(c)(d)</sup>	64.4 m	72.0 m	78.7 m
% of prescriptions dispensed at benchmark level	83%	82%	81%

**Notes:**

(a) A brand is defined as a unique combination of 'brand name' and 'form and strength'.

These counts were taken as at June of the financial year.

(b) Weighted average brand premium is calculated by:

scripts x premium = total premium value

total premium value / total scripts = weighted average brand premium

(c) Subsidised (over co-payment) scripts only.

(d) Includes only items where at least one brand is listed with a premium.

Expenditure and Prescriptions 2015-16.

Table 20(a): Pharmaceutical Benefits Scheme History - Scripts, 1948-49 to 2015-16

PRESCRIPTIONS	GENERAL	PENSIONER	CONC	S/NET	TOTAL	Drs Bag	TOTAL - ALL SCRIPTS
1948/49	280,719				280,719		280,719
1949/50	484,210				484,210		484,210
1950/51	3,758,622				3,758,622		3,758,622
1951/52	6,515,668	1,655,570			8,171,238		8,171,238
1952/53	6,853,937	2,766,947			9,620,884		9,620,884
1953/54	7,004,421	3,453,551			10,457,972		10,457,972
1954/55	9,201,387	4,418,633			13,620,020		13,620,020
1955/56	8,970,890	5,235,013			14,205,903		14,205,903
1956/57	9,045,439	5,580,946			14,626,385		14,626,385
1957/58	10,309,446	6,313,214			16,622,660		16,622,660
1958/59	13,253,168	6,821,578			20,074,746		20,074,746
1959/60	16,624,342	8,028,968			24,653,310		24,653,310
1960/61	20,489,065	10,727,570			31,216,635		31,216,635
1961/62	26,050,370	11,664,036			37,714,406		37,714,406
1962/63	29,517,810	12,674,230			42,192,040		42,192,040
1963/64	31,039,624	13,317,273			44,356,897		44,356,897
1964/65	33,714,429	13,841,372			47,555,801		47,555,801
1965/66	35,084,551	14,908,393			49,992,944		49,992,944
1966/67	36,750,907	16,936,435			53,687,342		53,687,342
1967/68	37,053,212	18,369,634			55,422,846		55,422,846
1968/69	40,453,366	19,954,471			60,407,837		60,407,837
1969/70	44,071,198	21,504,166			65,575,364		65,575,364
1970/71	48,971,406	22,515,117			71,486,523		71,486,523
1971/72	48,491,692	23,950,503			72,442,195		72,442,195
1972/73	49,115,497	25,560,576			74,676,073		74,676,073
1973/74	59,499,823	27,788,036			87,287,859		87,287,859
1974/75	67,350,637	30,323,662			97,674,299		97,674,299
1975/76	67,722,534	33,394,757			101,117,291		101,117,291
1976/77	56,099,277	33,606,128			89,705,405		89,705,405
1977/78	57,751,904	35,414,619			93,166,523		93,166,523
1978/79	53,553,036	39,409,489			92,962,525		92,962,525
1979/80	46,624,224	42,450,386			89,074,610		89,074,610
1980/81	47,619,120	46,778,057			94,397,177		94,397,177
1981/82	53,834,648	49,739,756			103,574,404		103,574,404
1982/83	50,078,929	52,529,929	2,931,462		105,540,320		105,540,320
1983/84	41,938,964	56,491,285	9,954,995		108,385,244		108,385,244
1984/85	50,690,275	60,069,806	10,068,817		120,828,898		120,828,898
1985/86	46,334,279	63,191,858	10,315,799		119,841,936		119,841,936
1986/87	28,762,909	64,243,148	9,755,680	2	102,761,737		102,761,737
1987/88	12,339,360	81,041,242	7,520,752	15,059,811	100,901,354		100,901,354
1988/89	14,078,934	78,283,599	8,223,231	11,925,271	100,585,764		100,585,764
1989/90	15,361,517	80,761,310	8,856,241	11,725,474	104,979,068		104,979,068
1990/91	10,608,974	36,868,817	36,588,405	11,675,164	95,741,360	558,899	96,300,259

*Expenditure and Prescriptions 2015-16.*

Notes

-Dr's Bag prior to 90/91 included in General, from 90/91 included in miscellaneous expenditure  
 -For 90/91 Concessional includes 'old' (prior to 1/11/90) prescriptions and 'new' (post 1/11/90) concessional category

Safety Net  
 Prior to 90/91 S/net for Gen & Concess is included in pensioner. In 90/91 free s/net is in both pensioner and s/net categories

PRESCRIPTIONS	GENERAL				CONCESSIONAL			TOTAL SCRIPTS	Drs Bag	TOTAL- ALL SCRIPTS
	NSN	S/NET 1	S/NET 2	TOTAL	NSN	S/NET	TOTAL			
1991/92	8,266,835	2,340,145	1,092,314	11,699,294	67,331,793	14,428,608	81,760,401	93,459,695	660,459	94,120,154
1992/93	10,260,426	3,917,022	2,800,496	16,977,944	71,756,325	16,757,840	88,514,165	105,492,109	689,508	106,181,617
1993/94	11,451,148	4,259,245	3,087,943	18,798,336	77,536,126	18,003,354	95,539,480	114,337,816	704,227	115,042,043
1994/95	13,491,364	4,695,314	2,072	18,188,750	82,400,588	17,457,008	99,857,596	118,046,346	674,331	118,720,677
1995/96	14,212,731	5,488,957	52	19,701,740	85,604,215	18,898,907	104,503,122	124,204,862	683,420	124,888,282
1996/97	14,709,601	3,082,843	14	17,792,458	85,965,797	19,676,007	105,641,804	123,434,262	665,301	124,099,563
1997/98	14,087,393	3,945,591	17	18,033,001	86,389,807	20,060,505	106,450,312	124,483,313	628,496	125,111,809
1998/99	15,153,975	4,111,091		19,265,066	88,475,327	20,608,073	109,083,400	128,348,466	572,753	128,921,219
1999/00	16,296,703	3,928,760		20,225,463	94,281,872	23,078,282	117,360,154	137,585,617	496,306	138,081,923
2000/01	18,526,141	4,340,364		22,866,505	99,285,160	25,420,114	124,705,274	147,571,779	478,999	148,050,778
2001/02	19,292,104	4,813,038		24,105,142	102,018,211	28,406,603	130,424,814	154,529,956	448,283	154,978,239
2002/03	20,694,131	5,188,492		25,882,623	101,459,056	31,177,491	132,636,547	158,519,170	437,516	158,956,686
2003/04	22,443,338	5,544,618		27,987,956	104,619,866	32,827,303	137,447,169	165,435,125	426,976	165,862,101
2004/05	22,194,451	6,209,302		28,403,753	105,377,946	36,095,311	141,473,257	169,877,010	402,492	170,279,502
2005/06	20,917,523	5,910,828		26,828,351	105,152,486	35,945,690	141,098,176	167,926,527	396,088	168,322,615
2006/07	19,871,669	4,710,422		24,582,091	110,917,202	32,675,864	143,593,066	168,175,157	360,362	168,535,519
2007/08	19,607,454	4,553,340		24,160,794	113,118,234	33,680,813	146,799,047	170,959,841	336,182	171,296,023
2008-09	20,746,777	5,580,636		26,327,413	119,906,347	35,234,371	155,140,718	181,468,131	367,996	181,836,127
2009-10	21,226,750	4,763,435		25,990,185	122,832,364	34,756,644	157,589,008	183,579,193	332,344	183,911,537
2010-11	21,032,398	4,943,233		25,975,631	125,446,923	36,381,986	161,828,909	187,804,540	337,715	188,142,255
2011-12	21,239,413	4,820,643		26,060,056	130,441,952	38,046,697	168,488,649	194,548,705	324,424	194,873,129
2012-13	19,323,589	4,371,046		23,694,635	133,646,630	39,611,994	173,258,624	196,953,259	352,123	197,305,382
2013-14	18,050,307	4,052,529		22,102,836	145,340,393	42,009,011	187,349,404	209,452,240	363,763	209,816,003
2014-15	15,902,515	3,544,902		19,447,417	147,979,717	44,277,679	192,257,396	211,704,813	380,376	212,085,189
2015-16	13,770,978	3,180,897		16,951,875	146,529,394	44,119,861	190,649,255	207,601,130	388,859	207,989,989

CONC: Concessional

S/NET: Safety Net

PENSIONER: Before 1 November 1990 pensioners received PBS drugs free of charge.

NSN: Non Safety Net

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.



Expenditure and Prescriptions 2015-16.

							FOR PBS	FOR SCRIPTS	SECT 100	
1991/92	128,988,053	6,043,066	135,031,119	173,201,117	173,201,117		308,232,236	1,427,723,765	100,877,826	1,528,601,591
1992/93	162,967,769	10,202,578	173,170,347	186,726,902	186,726,902		359,897,249	1,763,312,589	101,552,426	1,864,865,015
1993/94	183,012,475	11,074,025	194,086,500	201,596,301	201,596,301		395,682,801	2,080,301,601	116,696,888	2,196,998,489
1994/95	218,094,751	12,207,816	230,302,567	214,241,512	214,241,512		444,544,079	2,326,257,667	109,621,215	2,435,878,882
1995/96	237,239,817	14,278,699	251,518,516	226,583,554	226,583,554		478,102,070	2,669,346,099	135,473,133	2,804,819,232
1996/97	269,715,066	8,375,980	278,091,046	252,104,590	252,104,590		530,195,636	2,862,745,758	205,545,012	3,068,290,770
1997/98	281,739,252	12,625,016	294,364,268	276,440,026	276,440,026		570,804,294	3,097,321,744	258,950,240	3,356,271,984
1998/99	305,064,052	13,155,417	318,219,469	283,117,963	283,117,963		601,337,432	3,383,612,397	287,469,135	3,671,081,532
1999/00	333,003,549	12,584,337	345,587,886	306,183,001	306,183,001		651,770,887	3,828,268,194	311,727,262	4,139,995,456
2000/01	392,432,536	14,353,837	406,786,373	337,379,028	337,379,028		744,165,401	4,554,392,472	347,901,802	4,902,294,274
2001/02	426,974,621	16,864,336	443,838,957	362,237,529	362,237,529		806,076,486	4,993,747,074	396,386,682	5,390,133,756

DOCTOR'S BAG - \$ - (included in miscellaneous from 90/91)

1990/91	12,255,895
1991/92	14,514,725
1992/93	16,082,655
1993/94	16,679,933
1994/95	15,674,643
1995/96	16,202,098
1996/97	15,769,173
1997/98	14,953,823
1998/99	13,370,491
1999/00	10,754,395
2000/01	10,343,534
2001/02	9,803,682

note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available  
-miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

GOVERNMENT EXPENDITURE - \$-

	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOV'T EXP
2002/03	\$747,049,026	\$169,693,390		\$916,742,416	\$2,741,874,040	\$907,119,434	\$3,648,993,474	\$4,565,735,890	\$477,352,298	\$5,043,088,188
2003/04	\$824,130,608	\$190,682,979		\$1,014,813,587	\$2,972,331,634	\$1,004,522,779	\$3,976,854,413	\$4,991,668,000	\$570,500,000	\$5,562,168,000
2004/05	\$850,690,906	\$222,668,220		\$1,073,359,125	\$3,077,033,801	\$1,145,497,231	\$4,222,531,032	\$5,295,890,157	\$668,500,000	\$5,964,390,157
2005/06	\$850,095,680	\$216,246,563		\$1,066,342,242	\$3,145,480,431	\$1,172,502,111	\$4,317,982,542	\$5,384,324,784	\$764,000,000	\$6,148,324,784
2006/07	\$890,275,536	\$174,127,771		\$1,064,403,307	\$3,333,875,949	\$1,067,478,074	\$4,401,354,023	\$5,465,757,330	\$886,500,000	\$6,352,257,330
2007/08	\$1,039,451,749	\$173,499,550		\$1,212,951,299	\$3,561,294,283	\$1,137,925,393	\$4,699,219,676	\$5,912,170,974	\$975,500,000	\$6,887,670,974
2008/09	\$1,220,279,806	\$217,487,483		\$1,437,767,290	\$3,909,584,010	\$1,216,050,241	\$5,125,634,250	\$6,563,401,540	\$1,081,400,000	\$7,644,801,540
2009/10	\$1,339,182,210	\$199,599,002		\$1,538,781,212	\$4,220,391,341	\$1,259,719,602	\$5,480,110,943	\$7,018,892,155	\$1,232,400,000	\$8,251,292,155
2010-11	\$1,412,781,352	\$211,944,918		\$1,624,726,270	\$4,367,739,898	\$1,330,682,636	\$5,698,422,533	\$7,323,148,803	\$1,335,500,000	\$8,658,648,803
2011-12	\$1,453,773,280	\$208,167,009		\$1,661,940,288	\$4,476,104,435	\$1,390,159,396	\$5,866,263,831	\$7,528,204,119	\$1,473,700,000	\$9,001,904,119
2012-13	\$1,339,654,102	\$169,213,844		\$1,508,867,945	\$4,209,086,581	\$1,351,536,398	\$5,560,622,979	\$7,069,490,924	\$1,812,600,000	\$8,882,090,924

PATIENT CONTRIBUTION - \$-

	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL COST FOR SCRIPTS	MISC and SECT 100	TOTAL
2002/03	\$470,306,937	\$18,698,099		\$489,005,036	\$370,426,183	-	\$370,426,183	\$859,431,219	\$5,425,167,109	\$477,352,298	\$5,902,519,407
2003/04	\$524,763,848	\$20,538,514		\$545,302,362	\$392,513,143	-	\$392,513,143	\$937,815,505	\$5,929,483,505	\$570,500,000	\$6,499,983,505
2004/05	\$572,963,103	\$23,742,733		\$596,705,836	\$443,930,641	-	\$443,930,641	\$1,040,636,477	\$6,336,526,634	\$668,500,000	\$7,005,026,634
2005/06	\$606,897,345	\$27,199,070		\$634,096,415	\$489,173,277	-	\$489,173,277	\$1,123,269,692	\$6,507,594,476	\$764,000,000	\$7,271,594,476
2006/07	\$596,483,266	\$22,154,622		\$618,637,888	\$532,682,972	-	\$532,682,972	\$1,151,320,859	\$6,617,078,189	\$886,500,000	\$7,503,578,189
2007/08	\$607,183,393	\$22,323,024		\$629,506,417	\$559,962,883	-	\$559,962,883	\$1,189,469,300	\$7,101,640,274	\$975,500,000	\$8,077,140,274
2008/09	\$663,449,571	\$27,928,829		\$691,378,400	\$617,378,323	-	\$617,378,323	\$1,308,756,723	\$7,872,158,263	\$1,081,400,000	\$8,953,558,263
2009/10	\$701,961,714	\$25,253,391		\$727,215,106	\$656,949,638	-	\$656,949,638	\$1,384,164,743	\$8,403,056,898	\$1,232,400,000	\$9,635,456,898
2010-11	\$707,968,006	\$26,706,262		\$734,674,267	\$689,108,592	-	\$689,108,592	\$1,423,782,860	\$8,746,931,663	\$1,335,500,000	\$10,082,431,663
2011-12	\$735,994,339	\$27,003,502		\$762,997,841	\$742,139,779	-	\$742,139,779	\$1,505,137,620	\$9,033,341,739	\$1,473,700,000	\$10,507,041,739
2012-13	\$689,036,554	\$25,352,649		\$714,389,203	\$781,002,893	-	\$781,002,893	\$1,495,392,096	\$8,564,883,021	\$1,812,600,000	\$10,377,483,021

Doctor's Bag - \$ - (included in miscellaneous from 90/91)

2002/03	\$9,510,606
2003/04	\$9,408,669
2004/05	\$9,365,803
2005/06	\$10,063,803
2006/07	\$10,698,205
2007/08	\$13,468,779
2008/09	\$14,533,302
2009/10	\$13,571,776
2010-11	\$14,228,520
2011-12	\$12,974,506
2012-13	\$14,755,085

note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available  
-miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments

Expenditure and Prescriptions 2015-16.

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.  
 CONC: Concessional  
 S/Net: Safety Net  
 GEN: General  
 NSN: Non Safety Net

MISC and SECT 100: Drugs provided through special programs and hospitals; Section 100 drugs.  
 HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.  
 PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

GOVERNMENT EXPENDITURE - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	MISC and SECT 100	TOTAL GOVT EXP	
2013-14	\$1,429,860,300	\$154,692,449		\$1,584,552,749	\$4,319,414,670	\$1,388,583,542	\$5,707,998,212	\$7,292,550,961	\$2,033,900,000	\$9,326,450,961	
2014-15	\$1,463,256,600	\$129,523,975		\$1,592,780,575	\$4,123,482,128	\$1,380,416,342	\$5,503,898,470	\$7,096,679,044	\$2,183,101,118	\$9,279,780,162	
2015-16	\$1,785,357,915	\$118,821,879		\$1,904,179,793	\$4,630,980,302	\$1,413,858,158	\$6,044,838,460	\$7,949,018,254	\$2,752,825,107	\$10,701,843,361	
PATIENT CONTRIBUTION - \$-											
	GENERAL-NSN	GEN S/Net 1	GEN S/Net 2	TOTAL GEN	CONC - NSN	CONC S/Net	TOTAL CONC	TOTAL FOR PBS	TOTAL FOR SCRIPTS	MISC and SECT 100	TOTAL
2013-14	\$656,913,329	\$23,915,012		\$680,828,341	\$864,226,399	-	\$864,226,399	\$1,545,054,740	\$8,837,605,701	\$2,033,900,000	\$10,871,505,701
2014-15	\$567,399,905	\$21,021,090		\$588,420,995	\$877,483,279	-	\$877,483,279	\$1,465,904,274	\$8,562,583,318	\$2,183,101,118	\$10,745,684,436
2015-16	\$494,124,051	\$19,115,443		\$513,239,494	\$880,965,644	-	\$880,965,644	\$1,394,205,138	\$9,343,223,391	\$2,752,825,107	\$12,096,048,498
<b>Doctor's Bag - \$ - (included in miscellaneous from 90/91)</b>											
2013-14	\$16,009,408										
2014-15	\$16,340,036										
2015-16	\$15,887,150										
note- from 91/92 all figures are sourced from Department of Human Services (DHS) processing where available -miscellaneous and section 100 expenditure sourced from Department of Health and DHS payments											

S/NET 1, S/NET 2: Between 1991 and 1993 there were 2 tiers in the general safety net. Some prescriptions supplied during this period were processed in 1994 or after and the two tier structure applied to these.  
 CONC: Concessional  
 S/Net: Safety Net  
 GEN: General  
 NSN: Non Safety Net

MISC and SECT 100: Section 100 programmes, Doctors' Bag and Safety Net Card expenditure.  
 HOSP & MISC: Drugs provided through special programs and hospitals; Section 100 drugs.  
 PENS: Before 1 November 1990 pensioners received PBS drugs free of charge.

## PBS INFORMATION LINE REPORT, 2015-2016

The PBS Information Line, established in 1990, is an Australia-wide service which gives information on all aspects of the Pharmaceutical Benefits Scheme to the general public, health professionals, consumer groups, and to other Government Departments and agencies.

During the period 1st July 2015 – 30th June 2016, the information line received **8,330** calls.

<b>Conclusion</b>	<b>Number of calls</b>	<b>%</b>
Satisfied	8,310	99.8
Dissatisfied	16	0.2
Abusive	4	0.0
<b>Total</b>	<b>8,330</b>	<b>100.00</b>

### Breakdown of calls by month:

<b>Month</b>	<b>Number of calls</b>	<b>%</b>
July 2015	783	9.40
August 2015	711	8.54
September 2015	734	8.81
October 2015	696	8.36
November 2015	873	10.48
December 2015	529	6.35
January 2016	764	9.17
February 2016	642	7.71
March 2016	615	7.38
April 2016	624	7.49
May 2016	676	8.12
June 2016	682	8.20
<b>Total</b>	<b>8,330</b>	<b>100.00</b>

### Breakdown of calls by issue:

<b>Issue</b>	<b>Number of calls</b>	<b>%</b>
Pharmacy Item	6,114	54.52
Safety Net Issue	4,110	36.65

Expenditure and Prescriptions 2015-16.

**Breakdown of calls: Pharmacy item issue**

<b>Pharmacy Item Issue</b>	<b>Number of calls</b>	<b>%</b>
Authority Scripts	1,320	21.59%
Listing Status Query	566	9.26%
Other	459	7.51%
Cost of Item to Patient	395	6.46%
Availability	367	6.00%
Claims/Processing	298	4.87%
Non PBS - Medicare/DHS	256	4.19%
Non PBS - Centrelink/DVA	188	3.07%
Refund - Failure to show entitlement	176	2.88%
Prescription Rules	171	2.80%
Section 100 items	162	2.65%
Prescriber/Dispenser Number	156	2.55%
Doctors Bag/Emergency Drug Supplies	149	2.44%
Centrelink Conc. Card	145	2.37%
Brand Price Premium	136	2.22%
Eligibility for the PBS	86	1.41%
Schedule	80	1.31%
Deletion of Item	72	1.18%
Restricted items	70	1.14%
Cost of Item to Gov't	67	1.10%
Taking & Sending Medicines Overseas	67	1.10%
PBAC	62	1.01%
Private Scripts (non-PBS)	62	1.01%
C'th Seniors Health Care Card	48	0.79%
PBS Website Enquiry	47	0.77%
Schedule 8 Drugs	47	0.77%
Closing the Gap	43	0.70%
Prescription Shopping	40	0.65%
RPBS enquiry	36	0.59%
SN20DR	36	0.59%
Regulation 24	35	0.57%
PBS Statistics	34	0.56%
Brand Substitution	33	0.54%
Patient Contribution	31	0.51%
Generic Medicines	23	0.38%
Repeats (Reg 25)	23	0.38%
HMR/DMMR	22	0.36%
Therapeutic Group Premium	22	0.36%
Public Hospitals and the PBS	15	0.25%
Special Access Scheme	15	0.25%

Expenditure and Prescriptions 2015-16.

IME	14	0.23%
Recip. Health Care Agreements	13	0.21%
Private Hospitals and the PBS	10	0.16%
Extemp. Prepared Item	9	0.15%
Hospital Reforms	4	0.07%
Budget 2015	2	0.03%
Special Patient Contribution	2	0.03%
Norfolk Island Reforms	0	0.00%
Price Disclosure	0	0.00%
<b>Totals</b>	<b>6,114</b>	<b>100%</b>

**Breakdown of calls: Safety net issue**

<b>Safety Net Issue</b>	<b>Number of calls</b>	<b>%</b>
Thresholds	1306	31.78%
Refund - Exceeded the SN Threshold	795	19.34%
General SN Query	673	16.37%
Recording Prescriptions	351	8.54%
Stationery	226	5.50%
Recordable Value	197	4.79%
Period	116	2.82%
SN Processing	115	2.80%
Families/Dependants	110	2.68%
Eligibility	56	1.36%
CombSafetyNet(separated couples)	45	1.09%
Joint Safety Net	38	0.92%
Lost Card/Supplementary Card	33	0.80%
Cross-Overs	25	0.61%
Change of Status	24	0.58%
<b>Totals</b>	<b>4,110</b>	<b>100%</b>

**NATIONAL DIABETES SERVICES SCHEME (NDSS)**

Since its establishment in 1987, Diabetes Australia (under Diabetes Australia Ltd) has assisted with the administration of the National Diabetes Services Scheme (NDSS) on behalf of the Australian Government under a multi-year agreement. The current agreement runs from 1 July 2016 until 30 June 2020.

The Scheme is managed by the Department of Health through the Diabetes Products Section, Pharmaceutical Access Branch, Pharmaceutical Benefits Division.

The NDSS provides access to products and services that support the self-management of diabetes at prices subsidised by the Australian Government. Products include syringes and needles, insulin infusion pump consumables, and blood and urine testing strips, and are available through Access Points nationally. Access Points comprise community pharmacies and very small numbers of other entities, such as health centres, hospitals and aged care facilities.

The growth rate of Registrants on the NDSS has fluctuated since 2011-12. These variations may be attributed to improvements in data cleansing processes under the previous NDSS Funding Agreement that ended on 30 June 2016.

Details of registrant numbers are as follows:

Number of persons with diabetes registered with NDSS						
Year	Insulin using	% change	Non insulin using	% change	Total	% change
1990-91	57,087		12,121		69,208	
1991-92	67,693	18.58%	19,479	60.70%	87,172	25.96%
1992-93	79,010	16.72%	29,476	51.32%	108,486	24.45%
1993-94	90,962	15.13%	42,643	44.67%	133,605	23.15%
1994-95	103,263	13.52%	58,300	36.72%	161,563	20.93%
1995-96	116,275	12.60%	76,772	31.68%	193,047	19.49%
1996-97	129,076	11.01%	98,810	28.71%	227,886	18.05%
1997-98	142,484	10.39%	128,162	29.71%	270,646	18.76%
1998-99	155,943	9.45%	161,678	26.15%	317,621	17.36%
1999-2000	169,306	8.57%	202,549	25.28%	371,855	17.08%
2000-01	182,327	7.69%	246,805	21.85%	429,132	15.40%
2001-02	195,294	7.11%	298,599	20.99%	493,893	15.09%
2002-03	207,632	6.32%	353,825	18.50%	561,457	13.68%
2003-04	219,718	5.82%	409,150	15.64%	628,868	12.01%
2004-05	231,563	5.39%	466,409	13.99%	697,972	10.99%
2005-06	243,023	4.95%	525,365	12.64%	768,388	10.09%
2006-07	255,482	5.13%	588,580	12.03%	844,062	9.85%
2007-08	275,527	7.85%	622,340	5.74%	897,867	6.37%
2008-09	289,940	5.23%	577,567	-7.19%	867,507	-3.37%
2009-10	303,768	7.69%	653,570	8.65%	957,338	8.35%
2010-11	329,142	8.35%	703,575	7.65%	1,032,717	7.87%
2011-12	325,360	-1.15%	712,261	12.35%	1,037,621	0.48%
2012-13	342,349	5.22%	744,511	4.53%	1,086,860	4.75%


### Expenditure and Prescriptions 2015-16.

2013-14	356,807	4.22%	776,605	4.31%	1,133,412	4.28%
2014-15	371,197	4.03%	804,983	3.65%	1,176,180	3.77%
2015-16	383,439	3.3%	827,812	2.84%	1,211,251	3%

The chart on the following page shows the NDSS expenditure from 1992-1993 to 2015-2016.

Total NDSS expenditure for the 2015-16 financial year was \$249.5 million. This includes Australian Government funding and Registrant co-payments and is an increase of \$15.7 million over the previous financial year.

### NATIONAL DIABETES SERVICES SCHEME Expenditure



**Community Pharmacy Agreement (CPA) Expenses Report, 2015-16.****Table 21: 2015-16 Actual Costs of Major Components of CPA\***

<b>Component</b>	<b>Expense</b>
Pharmacy remuneration	\$2,493,251,200
Wholesale remuneration	\$388,422,533
Professional programmes	\$156,338,304
Community Services Obligation (CSO)	\$195,220,000
<b>Total</b>	<b>\$3,233,232,036</b>

\* The current Community Pharmacy Agreement is the 6th CPA.

**NOTES**

1. Details on how the above figures were identified are provided in the accompanying data tables. The above summary figures should be read in conjunction with the notes provided against each data table.

2. Professional programmes and CSO figures are accrual based, as the data used to identify the amounts are based on SAP records, which is an accrual based system.

3. The pharmacy remuneration figure is on a cash basis, as the data used to identify this amount was based on the Line by Line (LBL) data set Health receives from Human Services. It was not possible to use the SAP data (accrual basis) for this component, as SAP data does not provide the breakdown between medicine cost and pharmacy remuneration cost elements, whereas the LBL does.

**Table 22: Remuneration for Community Pharmacies and Friendly Societies<sup>1</sup>, 2015-16**

Pharmacy remuneration recognises the cost to the approved pharmacist for the purchase of the medicines; the administration, handling and storage costs entailed in dispensing medicines by the pharmacy (including associated infrastructure costs); and a pharmacist's specialised skills in dispensing the medicines.

	Expenses for PBS and RPBS	2014-15	2015-16	Change	Percentage Change
<b>Price to Pharmacists</b>					
	Ex-Manufacturer Price	\$6,479,093,813	\$6,685,360,750	\$206,266,937	3.2%
	Wholesale Mark-up	\$405,989,214	\$388,422,533	-\$17,566,682	-4.3%
	<b>Sub total</b>	<b>\$6,885,083,027</b>	<b>\$7,073,783,282</b>	<b>\$188,700,255</b>	<b>2.7%</b>
<b>Administration, Handling and Storage Costs</b>					
	Pharmacy Mark-up <sup>2</sup>	\$614,636,677	\$850,751,223	\$236,114,546	38.4%
	<b>Sub total</b>	<b>\$614,636,677</b>	<b>\$850,751,223</b>	<b>\$236,114,546</b>	<b>38.4%</b>
	*Known as the AHI in 6CPA				
<b>Pharmacist's Specialised Skills in Dispensing the Medicines</b>					
	Dispensing Fee	\$1,486,198,932	\$1,489,150,997	\$2,952,066	0.2%
	Dangerous Drug Fee	\$21,396,782	\$23,928,896	\$2,532,114	11.8%
	Wastage	\$2,183,394	\$2,941,014	\$757,620	34.7%
	Container Fee	\$258,564	\$293,593	\$35,030	13.5%
	<b>Sub total</b>	<b>\$1,510,037,671</b>	<b>\$1,516,314,501</b>	<b>\$6,276,829</b>	<b>0.4%</b>
<b>Other</b>					
	Premium Free Dispensing Incentive <sup>3</sup>	\$227,533,298	\$117,020,523	-\$110,512,775	-48.6%
	Electronic Prescription Fee <sup>4</sup>	\$8,091,750	\$9,164,954	\$1,073,203	13.3%
	<b>Sub total</b>	<b>\$235,625,048</b>	<b>\$126,185,477</b>	<b>-\$109,439,571</b>	<b>-46.4%</b>
	<b>Total<sup>5</sup></b>	<b>\$9,245,382,424</b>	<b>\$9,567,034,482</b>	<b>\$321,652,059</b>	<b>3.5%</b>

**Summary of Medicines, Wholesalers, and Pharmacy Expenses**

Medicines	\$6,479,093,813	\$6,685,360,750	\$206,266,937	3.2%
Wholesale	\$405,989,214	\$388,422,533	-\$17,566,682	-4.3%
Pharmacy	\$2,360,299,397	\$2,493,251,200	\$132,951,803	5.6%
<b>Total</b>	<b>\$9,245,382,424</b>	<b>\$9,567,034,482</b>	<b>\$321,652,059</b>	<b>3.5%</b>

The tables above refer to remuneration from over co-payment scripts. Remuneration from under co-payment scripts has not been included.

**Notes:**

1. Table 22 is for PBS and RPBS prescriptions claimed by community pharmacies and friendly societies for both Section 85 and some Section 100 items. It includes Government and patient contributions. It does not include:  
 \* EFC (as the calculations of the components from the Line by Line (LBL) data was not available for EFC in 2015-16. This will be available for the 2016-17 report);  
 \* hospital PBS claims for s85 items (as the report's focus is for community pharmacy);  
 \* some private hospital HSD claims; and  
 \* most public hospital HSD claims.

Given what data is and is not included, this table may not be directly comparable to earlier tables in this publication.

2. Pharmacy Mark-up: the increase in the pharmacy mark up between 2014-15 and 2015-16 is a result of the introduction of the Administration Handling and Infrastructure fee, replacing the previous percentage based mark-up.

3. Premium Free Dispensing Incentive: the reduction in PFDI remuneration is as a result of a 2015-16 Budget measure to better target the incentive for consumers to choose a brand without a price premium.

4. Electronic Prescription Fee is listed as a programme under 6CPA.

5. Health's 2015-16 Annual Report lists the administered expenses for pharmaceutical benefits as \$10.838 billion. The difference between that figure and the total figure above is attributable to:

\* the annual report does not include patient contributions;  
 \* the annual report data is based on accrual figures, whilst the above data is cash basis;  
 \* the annual report data does not include PFDI or EPC;  
 \* the annual report is PBS only and does not include RPBS, whereas the above data includes RPBS; and  
 \* the annual report captures all s85 and s100 accrued expenses (including all HSDs and EFC), while the above data captures all s85 and some s100 data for community pharmacy and friendly societies only (it excludes a number of smaller s100 programmes, for example growth hormone, IVF, botox, and Remote Area Aboriginal Health Services Programme).

**Table 23: CPA Professional Pharmacy Programmes Expenditure, 2015-16.**

Under the Sixth CPA there were a range of professional programmes and services delivered by community pharmacy and pharmacists to support the primary health care needs of consumers. The following table details the funds spent on these programmes under CPA in 2015-16 by relevant categories.

<b>Program Type</b>	<b>Actual Expenditure</b>
Rural Pharmacy Maintenance Allowance	\$14,139,418
Rural Pharmacy Workforce Program	\$6,865,988
Medication Management services	\$59,440,198
Medication Adherence services	\$65,600,000
Prescribing and Medication practices (ERRCD)	\$51,982
Aboriginal & Torres Strait Islander programs	\$4,555,958
Pharmacy Guild administration fees	\$5,684,760
<b>Programs Total</b>	<b>\$156,338,304</b>

**Notes:**

1. For the Programs administration arrangements for 2015-16 (administered by the Pharmacy Guild), the total funding provided to the Pharmacy Guild was \$156, 118, 117 (accrual figure). Of this, \$5,520,000 was provided to the Pharmacy Guild for the purpose of Pharmacy Guild administration fees. This means the Pharmacy Guild administration fees was 3.54% of the total funds.

2. The difference between total funds provided to the Pharmacy Guild (see note 1) and the total funds in the above table is related to some non-Guild administered Programs (e.g. Electronic Recording and Reporting of Controlled Drugs - ERRCD and the EPF) and a range of other program support activities (e.g. geospatial calculations, professional practice guidelines etc.).

3. The Electronic Prescription Fees (EPF) program expenditure is separately reported in Table 22 of the report.

4. Medication Management services, Medication Adherence Services and Aboriginal and Torres Strait Islander Programs are made up of multiple elements, as per the following tables.

**Medication Management services consist of the following elements:**

Diabetes Medscheck and Medscheck	\$10,936,753
Residential Medication Management Review (RMMR)	\$14,200,000
Home Medicines Review (HMR)	\$14,500,000
Clinical Interventions by pharmacists (Pharmacy Practice Incentives)	\$19,800,000
<b>Total</b>	<b>\$59,436,753</b>

\* The figure for Medication Management services in Table 23 above (\$59,440,198), also includes communication material storage costs (\$3,444.94)

**Medication Adherence services consist of the following elements:**

Dose Administration Aids (Pharmacy Practice Incentives)	\$58,400,000
Staged Supply (Pharmacy Practice Incentives)	\$7,200,000
<b>Total</b>	<b>\$65,600,000</b>

**Aboriginal & Torres Strait Islander Programs consist of the following elements:**

Workforce (scholarships)	\$180,000
Workforce (traineeships)	\$160,000
Supporting s100 Remote Aboriginal Area Health Services (RAAHS)	\$1,686,000
Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander people (QUMAX)	\$2,529,958
<b>Total</b>	<b>\$4,555,958</b>

**Table 24: Community Services Obligation (CSO) Expenditure, 2015-16.**

The CSO for pharmaceutical wholesalers helps to ensure there are arrangements in place for all Australians to have access to PBS medicines, via their community pharmacy, in a timely manner.

Administration of the CSO funding pool is conducted by the Australian Healthcare Associates under contract to the Department of Health.

<b>Element</b>	<b>Amount</b>
CSO funding pool	\$193,917,883
CSO admin	\$1,302,117
<b>Total</b>	<b>\$195,220,000</b>

**Table 25(a) and 25(b): Community Pharmacy Discounted Scripts, 2015-16.**

From 1 January 2016 to 30 June 2016 by Date of Supply.

**Table 25(a): Community Pharmacy Scripts With and Without \$1 Discount by Patient Category.**

Script Type	Concessional		General		RPBS		Total	
	Sum	%	Sum	%	Sum	%	Sum	%
<b>Discounted</b>	24,782,555	30.3	1,653,966	25.6	889,611	20.5	27,326,132	29.5
<b>Non-discounted</b>	57,030,101	69.7	4,801,157	74.4	3,460,006	79.6	65,291,264	70.5
<b>Total</b>	<b>81,812,656</b>	<b>100.0</b>	<b>6,455,123</b>	<b>100.0</b>	<b>4,349,617</b>	<b>100.0</b>	<b>92,617,396</b>	<b>100.0</b>

**Table 25(b): Community Pharmacy Scripts With \$1 Discount Showing Discount Range by Patient Category.**

Discount Range	Concessional		General		RPBS		Total	
	Sum	%	Sum	%	Sum	%	Sum	%
<b>&lt; \$0.50</b>	342,973	1.4	20,984	1.3	15,554	1.8	379,511	1.4
<b>&gt;= \$0.50 and &lt; \$1.00</b>	127,464	0.5	12,835	0.8	3,175	0.4	143,474	0.5
<b>\$1.00</b>	24,104,371	97.3	1,605,666	97.1	864,385	97.2	26,574,422	97.3
<b>Other</b>	207,747	0.8	14,481	0.9	6,497	0.7	228,725	0.8
<b>Total</b>	<b>24,782,555</b>	<b>100.0</b>	<b>1,653,966</b>	<b>100.0</b>	<b>889,611</b>	<b>100.0</b>	<b>27,326,132</b>	<b>100.0</b>

**Notes:**

Community Pharmacy scripts only.

Includes both Section 85 & Section 100 items.

Excludes Under Co-payment and Doctors Bag scripts.

Extracted by Date of Processing between 1 January 2016 and 30 September 2016.